

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **September 30, 2019**

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number **001-36464**

---

**Agile Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**23-2936302**  
(I.R.S. Employer Identification No.)

**101 Poor Farm Road**  
**Princeton, New Jersey 08540**  
(Address including zip code of principal executive offices)

**(609) 683-1880**  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol</u>	<u>Name of exchange on which registered:</u>
Common stock, par value \$0.0001 per share	AGRX	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

There were 59,302,126 shares of the registrant's common stock, \$0.0001 par value, outstanding as of October 28, 2019.

---

---

---

---

**Agile Therapeutics, Inc.**  
**Quarterly Report on Form 10-Q**  
**For the Quarter Ended September 30, 2019**

**Table of Contents**

<a href="#">PART I: FINANCIAL INFORMATION</a>	1
<a href="#">Item 1. Financial Statements</a>	1
<a href="#">Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>	16
<a href="#">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a>	30
<a href="#">Item 4. Controls and Procedures</a>	31
<a href="#">PART II: OTHER INFORMATION</a>	
<a href="#">Item 1. Legal Proceedings</a>	31
<a href="#">Item 1A. Risk Factors</a>	31
<a href="#">Item 6. Exhibits</a>	35

## SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “designed,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned development, commercialization, and market uptake of Twirla® (AG200-15) and our other potential product candidates, the timing of our commercial launch of Twirla® (AG200-15) the strength and breadth of our intellectual property, our ongoing and planned clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the legal and regulatory landscape impacting our business, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our development and validation of manufacturing capabilities, our results of operations, financial condition and liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.

Some of the factors that we believe could cause actual results to differ from those anticipated or predicted include:

- our available cash and our ability to obtain additional funding to fund our business plan without delay and to continue as a going concern;
- the potential that the U.S. Food and Drug Administration, or FDA, determines that our data does not support approval of the Twirla new drug application, or NDA, and requires us to conduct additional studies or reformulate Twirla to address the concerns raised in the second Twirla complete response letter, or 2017 CRL;
- our ability to obtain a favorable advisory committee vote regarding the benefit and risk profile of Twirla, which is currently planned for October 30, 2019;
- our ability to obtain and maintain regulatory approval of the Twirla NDA and our product candidates, and the labeling under any approval we may obtain;
- our ability to attract and retain key employees;
- the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;

## [Table of Contents](#)

- our third-party manufacturer, Corium International, Inc.’s, or Corium, inability to complete any work or provide any data and other information necessary to support the resubmission and approval of our Twirla NDA;
- our ability along with Corium to successfully scale-up of the commercial manufacturing process for Twirla, including the qualification and validation of equipment related to the expansion of Corium’s manufacturing facility;
- the performance and financial condition of Corium or any of the suppliers to our third-party manufacturer;
- the success and timing of our clinical trials or other studies;
- our ability along with our study investigators to pass any FDA inspections of our clinical sites;
- regulatory and legislative developments in the United States and foreign countries, which could include, among other things, a government shutdown;
- our plans to commercialize Twirla and develop our other potential product candidates;
- the size and growth of the potential markets for our product candidates and our ability to serve those markets;
- the rate and degree of market acceptance of any of our product candidates;
- our ability to obtain and maintain intellectual property protection for our product candidates;
- the successful development of our sales and marketing capabilities;
- our inability to timely obtain from our third-party manufacturer, Corium, sufficient quantities or quality of our product candidates or other materials required for a clinical trial or other tests and studies; and
- our ability to successfully implement our business strategy.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q. You should also read carefully the factors described in the “Risk Factors” included in Part II, Item 1A of this Quarterly Report and Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the Securities and Exchange Commission on March 12, 2019 to better understand significant risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.

This Quarterly Report on Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.

[Table of Contents](#)

We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Twirla® is one of our trademarks used in this Form 10-Q. This Form 10-Q also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Form 10-Q may appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.

**Agile Therapeutics, Inc.**  
**Part I — Financial Information**

**ITEM 1. Financial Statements**

**Agile Therapeutics, Inc.**  
**Balance Sheets**  
**(Unaudited)**  
**(in thousands, except par value and share data)**

	September 30, 2019	December 31, 2018
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 18,370	\$ 7,851
Prepaid expenses	1,316	607
Total current assets	19,686	8,458
Property and equipment, net	13,932	13,916
Right of use and other assets	214	18
<b>Total assets</b>	<b>\$ 33,832</b>	<b>\$ 22,392</b>
<b>Liabilities and stockholders' equity</b>		
Current liabilities:		
Accounts payable	\$ 603	\$ 875
Accrued expenses	1,114	1,343
Lease liability, current portion	178	—
Total current liabilities	1,895	2,218
Lease liability, long-term	34	—
<b>Commitments and contingencies (Note 12)</b>		
<b>Stockholders' equity</b>		
Common stock, \$.0001 par value, 150,000,000 shares authorized, 59,302,126 and 34,377,329 issued and outstanding at September 30, 2019 and December 31, 2018, respectively	6	3
Additional paid-in capital	286,246	261,722
Accumulated deficit	(254,349)	(241,551)
<b>Total stockholders' equity</b>	<b>31,903</b>	<b>20,174</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 33,832</b>	<b>\$ 22,392</b>

*See accompanying notes to unaudited financial statements.*

**Agile Therapeutics, Inc.**  
**Statements of Operations**  
**(Unaudited)**  
**(in thousands, except par value and share data)**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2019	2018	2019	2018
Operating expenses:				
Research and development	\$ 2,361	\$ 1,549	\$ 7,021	\$ 7,921
General and administrative	2,138	1,767	5,732	7,173
Restructuring costs	—	299	—	715
Total operating expenses	<u>4,499</u>	<u>3,615</u>	<u>12,753</u>	<u>15,809</u>
Loss from operations	<u>(4,499)</u>	<u>(3,615)</u>	<u>(12,753)</u>	<u>(15,809)</u>
Other income (expense)				
Interest income	67	91	168	289
Interest expense	—	(268)	—	(955)
Change in fair value of warrants	—	—	—	29
Total other income (expense), net	<u>67</u>	<u>(177)</u>	<u>168</u>	<u>(637)</u>
Loss before benefit from income taxes	(4,432)	(3,792)	(12,585)	(16,446)
Benefit from income taxes	—	—	—	477
Net loss	<u>\$ (4,432)</u>	<u>\$ (3,792)</u>	<u>\$ (12,585)</u>	<u>\$ (15,969)</u>
Net loss per share (basic and diluted)	<u>\$ (0.08)</u>	<u>\$ (0.11)</u>	<u>\$ (0.28)</u>	<u>\$ (0.47)</u>
Weighted-average common shares (basic and diluted)	<u>53,609,511</u>	<u>34,377,329</u>	<u>44,957,809</u>	<u>34,295,240</u>

*See accompanying notes to unaudited financial statements.*



**Agile Therapeutics, Inc.**  
**Statements of Changes in Stockholders' Equity**  
**(Unaudited)**  
**(in thousands)**

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Number of Shares	Amount			
Balance December 31, 2018	34,377,329	\$ 3	\$ 261,722	\$ (241,551)	\$ 20,174
Adjustment to derivative liabilities upon adoption of ASU 2017-11	—	—	213	(213)	—
Share-based compensation - stock options and RSUs	—	—	490	—	490
Issuance of common stock in private placement, net of expenses	8,426,750	1	7,809	—	7,810
Issuance of common stock pursuant to at-the-market stock sales, net of expenses	665,974	—	860	—	860
Vesting of RSUs	145,204	—	—	—	—
Net loss	—	—	—	(4,669)	(4,669)
Balance March 31, 2019	43,615,257	\$ 4	\$ 271,094	\$ (246,433)	\$ 24,665
Share-based compensation - stock options	—	—	479	—	479
Issuance of common stock pursuant to at-the-market stock sales, net of expenses	992,072	—	1,389	—	1,389
Issuance of common stock upon exercise of stock options	25,000	—	15	—	15
Net loss	—	—	—	(3,484)	(3,484)
Balance June 30, 2019	44,632,329	\$ 4	\$ 272,977	\$ (249,917)	\$ 23,064
Share-based compensation - stock options	—	—	378	—	378
Proceeds from issuance of common stock in public offering, net of expenses	14,526,315	1	12,686	—	12,687
Issuance of common stock pursuant to at-the-market stock sales, net of expenses	143,482	1	205	—	206
Net loss	—	—	—	(4,432)	(4,432)
Balance September 30, 2019	<u>59,302,126</u>	<u>\$ 6</u>	<u>\$ 286,246</u>	<u>\$ (254,349)</u>	<u>\$ 31,903</u>

*See accompanying notes to unaudited financial statements.*

**Agile Therapeutics, Inc.**  
**Statements of Changes in Stockholders' Equity**  
**(Unaudited)**  
**(in thousands)**

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Number of Shares	Amount			
Balance December 31, 2017	34,186,342	\$ 3	\$ 258,092	\$ (221,772)	\$ 36,323
Share-based compensation - stock options and RSUs	—	—	1,119	—	1,119
Vesting of RSUs	61,926	—	—	—	—
Net loss	—	—	—	(6,833)	(6,833)
Balance March 31, 2018	34,248,268	\$ 3	\$ 259,211	\$ (228,605)	\$ 30,609
Share-based compensation - stock options and RSUs	—	—	987	—	987
Vesting of RSUs	129,061	—	—	—	—
Net loss	—	—	—	(5,344)	(5,344)
Balance June 30, 2018	34,377,329	\$ 3	\$ 260,198	\$ (233,949)	\$ 26,252
Share-based compensation - stock options and RSUs	—	—	721	—	721
Net loss	—	—	—	(3,792)	(3,792)
Balance September 30, 2018	<u>34,377,329</u>	<u>\$ 3</u>	<u>\$ 260,919</u>	<u>\$ (237,741)</u>	<u>\$ 23,181</u>

*See accompanying notes to unaudited financial statements.*

**Agile Therapeutics, Inc.**  
**Statements of Cash Flows**  
**(Unaudited)**  
**(in thousands)**

	Nine Months Ended September 30,	
	2019	2018
<b>Cash flows from operating activities:</b>		
Net loss	\$ (12,585)	\$ (15,969)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	14	18
Amortization	107	—
Noncash stock based compensation	1,347	2,827
Noncash interest	—	367
Change in fair value of warrants	—	(29)
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	(709)	31
Accounts payable and accrued expenses	(481)	(1,004)
Lease liability	(112)	—
Net cash used in operating activities	<u>(12,419)</u>	<u>(13,759)</u>
<b>Cash flows from investing activities:</b>		
Acquisition of property and equipment	(30)	(318)
Net cash used in investing activities	<u>(30)</u>	<u>(318)</u>
<b>Cash flows from financing activities:</b>		
Proceeds from issuance of common stock in private placement, net of offering costs	7,810	
Proceeds from At-the-Market sales of common stock, net of offering costs	2,456	
Proceeds from issuance of common stock in public offering, net of offering costs	12,687	
Principal payments of loan payable	—	(4,949)
Proceeds from exercise of stock options	15	—
Net cash provided by (used in) financing activities	<u>22,968</u>	<u>(4,949)</u>
Net increase (decrease) in cash and cash equivalents	10,519	(19,026)
Cash and cash equivalents, beginning of period	7,851	35,952
Cash and cash equivalents, end of period	<u>\$ 18,370</u>	<u>\$ 16,926</u>
<b>Supplemental disclosure of noncash financing activities</b>		
<b>Supplemental cash flow information</b>		
Interest paid	\$ —	\$ 625
Cash paid for income taxes	\$ —	\$ —

*See accompanying notes to unaudited financial statements.*

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

**1. Organization and Description of Business**

**Nature of Operations**

Agile Therapeutics, Inc. (“Agile” or the “Company”) was incorporated in Delaware on December 22, 1997. Agile is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. The Company’s activities since inception have consisted principally of raising capital and performing research and development, including development of the Company’s lead product candidate Twirla<sup>®</sup>, also known as AG200-15. The Company is headquartered in Princeton, New Jersey.

Twirla<sup>®</sup> is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Substantially all of the Company’s resources are currently dedicated to developing and seeking regulatory approval for Twirla in the United States. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including, but not limited to, dependence on key individuals, the difficulties and uncertainties inherent in the development of commercially usable products, market acceptance of products, protection of proprietary technology, the potential need to obtain additional capital necessary to fund the development of its products, competition from larger companies and compliance with U.S. Food and Drug Administration (the “FDA”) and other government regulations. If the Company does not successfully commercialize any product candidates, it will be unable to generate recurring product revenue or achieve profitability. The Company has incurred operating losses and negative cash flows from operating activities each year since inception. As of September 30, 2019, the Company had an accumulated deficit of approximately \$254.3 million. The Company expects to continue to incur net losses into the foreseeable future.

The Company has financed its operations to date primarily through the issuance and sale of its common stock in both public and private offerings (see Note 8), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding.

*Going Concern*

On December 21, 2017, the Company received a complete response letter (the “2017 CRL”) from the FDA citing deficiencies related to the manufacturing process for Twirla and raising questions on the *in vivo* adhesion properties of Twirla and their potential relationship to the Company’s Phase 3 clinical trial results. The Company’s ability to commercialize Twirla, and the timing of Twirla commercialization, is dependent on the FDA’s review of the Company’s response to the 2017 CRL and its new drug application (“NDA”) for Twirla, and other items such as timely and successful completion of the validation of equipment for commercial manufacturing, ultimate FDA approval, and the Company’s ability to secure additional capital. In January 2018, following the Company’s receipt of the 2017 CRL, the Company significantly scaled back its preparations for commercialization of Twirla, including commercial pre-launch and manufacturing validation activities, pending its ability to address the 2017 CRL and receive approval of Twirla. In April 2018, the Company met with the FDA in a Type A meeting to discuss the deficiencies in the Twirla NDA and the regulatory path for approval of Twirla, and the Company announced the content of the official minutes from the meeting in May 2018.

In June 2018, the Company announced it had submitted a formal dispute resolution request (“FDRR”) with the FDA for Twirla. The dispute pertained to the determination from the FDA’s reviewing Division of Bone, Reproductive and Urologic Products (“DBRUP”) that concerns surrounding the *in vivo* adhesion properties of Twirla prevent the approval and could not be addressed through the Company’s proposed patient compliance programs. The initial FDRR was submitted in June 2018 and was reviewed by the Office of Drug Evaluation III, which denied the Company’s appeal on July 20, 2018. The Company then escalated its appeal to the Office of New Drugs (“OND”).

In October 2018, the OND formally denied the Company’s appeal and provided a path forward that may not require that the Company reformulate Twirla or conduct a bioequivalence study between formulations, as previously suggested by DBRUP. Specifically, OND suggested that the Company conduct a wear study to evaluate whether Twirla demonstrates a generally similar adhesion performance to Xulane<sup>®</sup>, the generic version of the previously marketed Ortho Evra<sup>®</sup> contraceptive patch, a product the FDA considers to have acceptable adhesion. If this result

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

**1. Organization and Description of Business (Continued)**

is demonstrated, OND stated that the study would support the conclusion of adequate Twirla adhesion. DBRUP later agreed that Twirla would show adequate adhesion if it demonstrated statistical non-inferiority to Xulane by a margin of less than +0.15. On February 11, 2019, the Company announced the top-line results of the comparative wear study, which demonstrated that Twirla was statistically non-inferior to Xulane. The wear study suggested by OND to address adhesion provides a path forward but is not intended to address efficacy. The Company resubmitted the NDA for Twirla which was received by the FDA on May 16, 2019 and the Company was given a target Prescription Drug User Fee Act ("PDUFA") goal date of November 16, 2019. The Company was also notified that a meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee of the FDA has been scheduled for October 30, 2019 to review the Company's NDA for Twirla. Twirla's efficacy, including the Pearl Index that FDA noted is substantially higher than other previously approved combined hormonal contraceptives when weighed against the FDA's view of the product candidate's safety profile, is the primary issue that the FDA plans to bring to Advisory Committee. In advance of the Advisory Committee meeting, the FDA issued its briefing document in which it expresses a number of concerns regarding Twirla's approvability, including, but not limited to concerns related to Twirla's efficacy when balanced against its safety. In its briefing materials, the FDA also did not appear to agree with our proposal to include a limitation of use based on patient weight and BMI in the product label.

The Company believes that its cash and cash equivalents as of September 30, 2019 will be sufficient to meet its operating requirements through the end of the first quarter of 2020. The Company will require additional capital to fund operating needs for the remainder of the first quarter of 2020 and beyond, which primarily will be used for the completion of our commercial plan for Twirla, if approved, including the completion of the validation of our commercial manufacturing process, the commercial launch, and advancing the development of our other potential product candidates. The Company cannot assure you that the FDA will approve Twirla, or that the Company along with Corium International, Inc. ("Corium"), its third-party manufacturer, will be able to complete validation of the Company's commercial manufacturing successfully and in a timely manner.

The Company anticipates it will continue to incur net losses for the foreseeable future and the Company's ability to continue operations for the remainder of 2020 and beyond will depend on its ability to obtain additional funding, as to which no assurances can be given. There can be no assurance that any financing by the Company can be realized by the Company, or if realized, what the terms of any such financing may be, or that any amount that the Company is able to raise will be adequate. Based upon the foregoing, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.

As of September 30, 2019, the Company had cash and cash equivalents of \$18.4 million. The Company continues to analyze various alternatives, including strategic and refinancing alternatives, asset sales and mergers and acquisitions. The Company's future success depends on its ability to raise additional capital and/or implement the various strategic alternatives discussed above. The Company cannot be certain that these initiatives or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company's current stockholders will experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company then may be unable to complete the development of Twirla, and may also be required to further cut operating costs, forego future development and other opportunities and may need to seek bankruptcy protection.

The unaudited financial statements as of September 30, 2019 have been prepared under the assumption that the Company will continue as a going concern for the next 12 months. The Company's ability to continue as a going concern is dependent upon its uncertain ability to obtain additional equity and/or debt financing and reduce expenditures. The accompanying financial statements as of September 30, 2019 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements.

**Basis of Presentation**

The accompanying unaudited interim financial statements have been prepared by the Company, without audit, in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

**1. Organization and Description of Business (Continued)**

information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2018 filed with the SEC.

In the opinion of management, the unaudited interim financial statements reflect all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future period.

**2. Summary of Significant Accounting Policies**

The Company’s complete listing of significant accounting policies is described in Note 2 to the Company’s audited financial statements as of December 31, 2018 included in its annual report on Form 10-K filed with the SEC.

**Use of Estimates**

The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for common stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.

**Fair Value of Financial Instruments**

In accordance with Accounting Standards Codification (“ASC”) 825, *Financial Instruments*, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note 3).

Other financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.

**Long-Lived Assets**

In accordance with ASC 360, *Property, Plant and Equipment*, the Company’s policy is to review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Management does not believe that there has been any impairment of the carrying value of any long-lived assets as of September 30, 2019.

**Warrants**

The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480 *Distinguishing Liabilities from Equity*. ASC 480 requires that a financial instrument, other than an outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer’s equity shares, regardless of the timing or the probability of the redemption feature and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using the Black-Scholes option-pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

**2. Summary of Significant Accounting Policies (Continued)**

In connection with the completion of the Company's initial public offering in May 2014, the warrants to purchase shares of Series A-1 and Series A-2 preferred stock expired unexercised and the warrants to purchase shares of Series C preferred stock automatically converted into warrants to purchase shares of common stock. Prior to January 1, 2019, warrants with non-standard anti-dilution provisions (referred to as down round protection) were classified as liabilities and re-measured each reporting period. On January 1, 2019, the Company adopted the provisions of Accounting Standards Update ("ASU") 2017-11 *Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception*, which indicates that a down round feature no longer precludes equity classification when assessing whether an investment is indexed to an entity's own stock. The Company used a modified retrospective approach to adoption, which does not restate its financial statements as of the prior year end (December 31, 2018). The cumulative effect of adoption of ASU 2017-11 resulted in an adjustment to accumulated deficit as of January 1, 2019 of \$213 with a corresponding adjustment to additional paid-in capital. As of September 30, 2019, there were outstanding 62,505 warrants to purchase common stock at \$6.00 per share. These warrants expire on December 14, 2019.

The warrants issued in connection with the Company's debt financing completed in February 2015 (see Note 7) are classified as a component of stockholders' equity. The value of such warrants was determined using the Black-Scholes option-pricing model. As of September 30, 2019, there were outstanding 180,274 warrants to purchase common stock at \$5.89 per share related to this debt financing. These warrants expire on February 24, 2020.

**Stock-Based Compensation**

The Company accounts for stock-based compensation in accordance with ASC 718, *Compensation—Stock Compensation*. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.

The Company also awards restricted stock units ("RSUs") to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. Cost associated with performance-based restricted stock units with a performance condition which affects the vesting is recognized only if the performance condition is probable of being satisfied.

**Net Loss Per Share**

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

## 2. Summary of Significant Accounting Policies (Continued)

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the three and nine months ended September 30, 2019 and 2018, respectively, because to do so would be anti-dilutive (in common equivalent shares):

	September 30,	
	2019	2018
Common stock warrants	242,779	242,779
Unvested restricted stock units	—	147,554
Common stock options	7,299,560	5,687,901
Total	<u>7,542,339</u>	<u>6,078,234</u>

## Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. The recent accounting pronouncements did not have a material impact of the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

## 3. Fair Value Measurements

ASC 820, *Fair Value Measurements and Disclosures*, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

- Level 1 — Quotes prices in active markets for identical assets and liabilities. The Company’s Level 1 assets consist of cash and cash equivalents. The Company has no Level 1 liabilities.
- Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities.
- Level 3—Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participant price the fair value of the assets or liabilities. The Company’s Level 3 liabilities consist of the warrant liability.

The Company is required to mark the value of its warrant liability to market and recognize the change in valuation in its statements of operations each reporting period.



**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
(in thousands, except share and per share data)

**3. Fair Value Measurements (Continued)**

The following table sets forth the Company's financial instruments measured at fair value by level within the fair value hierarchy as of September 30, 2019 and December 31, 2018.

	Level 1	Level 2	Level 3
<b>September 30, 2019</b>			
Assets:			
Cash and cash equivalents	\$ 18,314	\$ —	\$ —
Total assets at fair value	<u>\$ 18,314</u>	<u>\$ —</u>	<u>\$ —</u>
<b>December 31, 2018</b>			
Assets:			
Cash and cash equivalents	\$ 7,776	\$ —	\$ —
Total assets at fair value	<u>\$ 7,776</u>	<u>\$ —</u>	<u>\$ —</u>
Liabilities:			
Common stock warrants	\$ —	\$ —	\$ —
Total liabilities at fair value	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>

As indicated in Note 2, on January 1, 2019, the Company adopted the provisions of ASU 2017-11 to account for the down round feature of its warrants issued in December 2012 and converted into warrants to purchase common stock in connection with its initial public offering in May 2014. As a result of the adoption of ASU 2017-11, effective January 1, 2019 the Company no longer measures these warrants at fair value

The significant assumptions used in preparing the option pricing model for valuing the Company's warrants as of December 31, 2018 include (i) volatility (70.0%), (ii) risk free interest rate of 2.57% (estimated using treasury bonds with a 1-year life), (iii) strike price (\$6.00) for the common stock warrants, (iv) fair value of common stock (\$0.58) and (v) expected life (1 year).

There were no transfers between Level 1, 2 or 3 during 2019 or 2018. If the Company's estimates regarding the fair value of its warrants are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly.

**4. Prepaid Expenses**

Prepaid expenses consist of the following:

	September 30, 2019	December 31, 2018
Prepaid insurance	\$ 788	\$ 484
Prepaid Advisory Committee Costs	353	—
Other	175	123
Total prepaid expenses	<u>\$ 1,316</u>	<u>\$ 607</u>

**5. Accrued Liabilities**

Accrued liabilities consist of the following:

	September 30, 2019	December 31, 2018
Employee bonuses	\$ 638	\$ 621
Accrued retention bonus	—	638
Accrued professional fees and other	476	84
Total accrued liabilities	<u>\$ 1,114</u>	<u>\$ 1,343</u>

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

## 6. Leases

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The Company adopted ASU No. 2016-02 on January 1, 2019. The Company recorded a lease asset and lease liability of approximately \$0.3 million on its balance sheet as of January 1, 2019, with no material impact on its statement of operations.

The Company has no finance leases and one operating lease for office space in Princeton, NJ. Operating lease expense was \$48 and \$145 for the three and nine months ended September 30, 2019, respectively.

Operating cash flows used for operating leases during the three and nine months ended September 30, 2019 were \$37 and \$112, respectively. As of September 30, 2019, the weighted-average remaining lease term was 1.2 years and the weighted average discount rate was 21.2%.

Future minimum lease payments under non-cancellable leases as of September 30, 2019 were as follows:

Remainder of 2019	\$	51
2020		190
Total	\$	241
Less: Interest		(29)
Present value of lease liability	\$	<u>212</u>

## 7. Loan and Security Agreement

### *Hercules Capital, Inc.*

In February 2015, the Company entered into a loan and security agreement (the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) for a term loan of up to \$25.0 million (the “Term Loan”). In August 2016, the Company entered into the First Amendment to Loan and Security Agreement (the “First Amendment”) with Hercules which amended certain terms of the Hercules Loan Agreement. In May 2017, the Company entered into the Second Amendment to Loan and Security Agreement (the “Second Amendment”) with Hercules which further amended certain terms of the Hercules Loan Agreement. A first tranche of \$16.5 million was funded upon execution of the Hercules Loan Agreement, approximately \$15.5 million of which was used to repay the Company’s existing term loan with Oxford Finance LLC.

The First Amendment provided that the Term Loan matured on December 1, 2018. In connection with the execution of the First Amendment, the Company paid Hercules a facility fee of \$165. The facility fee represented a debt issue cost which was reflected as a reduction to the carrying amount of the loan payable in accordance with ASU 2015-03. Such issue costs were amortized to interest expense over the life of the Term Loan using the effective interest method.

The Term Loan accrued interest at a rate of the greater of 9.0% or 9.0% plus Prime minus 4.25% and was payable monthly. Principal was due in 23 consecutive monthly installments beginning on February 1, 2017 and ending on December 1, 2018. In addition to the outstanding principal balance, the Company was required to make a final payment of approximately \$611 on the maturity date of the Term Loan (December 1, 2018). The amount of the end of term final payment was accrued over the loan term as interest expense.

In connection with the Hercules Loan Agreement, the Company issued Hercules a warrant to purchase 180,274 shares of the Company’s common stock at an exercise price of \$5.89 per share which expires on February 24, 2020 and granted Hercules the right to participate in future equity financings in an amount up to \$2.0 million while the loan and warrant are outstanding.

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

**7. Loan and Security Agreement (Continued)**

The Company allocated the proceeds of \$16.5 million in accordance with ASC 470 based on the relative fair values. The relative fair value of the warrants of approximately \$1.2 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The significant assumptions used in preparing the option pricing model for valuing the Company's warrant issued to Hercules include (i) volatility (75.0%), (ii) risk free interest rate of 1.22% (estimated using treasury bonds with a 4-year life), (iii) strike price (\$5.89) for the common stock warrant, (iv) fair value of common stock (\$9.82) and (v) expected life (4 years). The discount on the debt was amortized to interest expense over the term of the debt.

Interest expense on the Hercules Loan Agreement including the accretion of the value of the related warrants, accrual of term loan back-end fee and amortization of the deferred financing costs was \$0, for the three and nine months ended September 30, 2019 and was approximately \$268 thousand and \$955 thousand for the three and nine months ended September 30, 2018, respectively.

**8. Stockholders' Equity**

*Shelf Registration Statement*

On November 2, 2018, the Company filed a universal shelf registration statement with the Securities and Exchange Commission ("SEC") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate amount of \$100.0 million (the "2018 Shelf Registration Statement"). On November 14, 2018, the 2018 Shelf Registration Statement was declared effective by the SEC. In the future, the Company may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered. At the time any of the securities covered by the 2018 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.

*Public Offering of Common Stock*

In August 2019, the Company completed a public offering of 14,526,315 shares of its common stock at a price of \$0.95 per share. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately \$12.7 million.

*Private Placement*

In March 2019, the Company completed a private placement of 8,426,750 shares of common stock at \$0.93 per share. Proceeds from the Company's private placement, net of offering costs were approximately \$7.8 million.

*ATM*

In January 2019, the Company entered into an ATM Agreement (the "2019 ATM Agreement") under which the Company was authorized to issue and sell shares of its common stock having aggregate sales proceeds of up to \$10.0 million from time to time. The Company paid a commission of 3% of the gross proceeds from the sales of its common stock under the 2019 ATM Agreement. For the nine months ended September 30, 2019, the Company sold 1,801,528 shares of common stock under the 2019 ATM Agreement, resulting in net proceeds of approximately \$2.5 million. The Company terminated the 2019 ATM Agreement on July 31, 2019.

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

**8. Stockholders' Equity (Continued)***Stock-Based Compensation Expense*

Stock-based compensation expense was allocated as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2019	2018	2019	2018
Research and development	\$ 103	\$ 286	\$ 413	\$ 975
General and administrative	275	435	934	1,852
Total	<u>\$ 378</u>	<u>\$ 721</u>	<u>\$ 1,347</u>	<u>\$ 2,827</u>

**9. Income Taxes***Sale of New Jersey Net Operating Losses*

In January 2018, the Company received net proceeds of approximately \$0.5 million in non-dilutive financing through the State of New Jersey's Technology Business Tax Certificate Transfer Program (the "Program"). The Program enables approved biotechnology companies to sell their unused Net Operating Loss Carryovers and unused Research and Development Tax Credits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The New Jersey Economic Development Authority and the New Jersey Department of the Treasury's Division of Taxation administer the Program. The Company used the proceeds from the sale for working capital purposes. The Company has now reached the maximum lifetime benefit of \$15.0 million under the Program and will no longer be eligible to participate in the Program.

**10. Restructuring Costs**

In June 2018, the Company announced a reduction in its workforce, which resulted in the termination of several employees primarily from the Company's commercial and clinical teams, representing approximately thirty percent of its employees. This workforce reduction, along with other reductions in planned operating expenses is designed to preserve cash while the Company pursued formal dispute resolution with the FDA for Twirla and determines a regulatory path forward for the resubmission of the Company's NDA for Twirla.

In June 2018, the Company also announced that it had adopted a retention plan (the "Retention Plan") to provide (i) cash retention payments to all remaining employees in order to induce such employees to remain employed by the Company through December 31, 2018 and (ii) stock option grants to all remaining employees in order to induce such employees to remain employed by the Company through December 31, 2019.

Each employee who participated in the Retention Plan ("Retention Plan Participants") and (i) remained continuously employed by the Company through December 31, 2018 or (ii) had been terminated by the Company other than for cause (as defined in an applicable employment agreement, or, if no employment agreement existed, as determined by the Company in good faith) prior to December 31, 2018, were paid a lump-sum cash payment in an amount determined by the compensation committee ("Compensation Committee") of the Company's board of directors at the time of the adoption of the Retention Plan. The total amount of the cash portion of the Retention Plan was approximately \$0.6 million and was paid out to the Retention Plan Participants in January 2019.

In addition, each Retention Plan Participant was granted a stock option to purchase the number of shares of common stock as approved by the Compensation Committee, with a per share exercise price of \$0.58, representing the closing price of the Company's common stock as reported by Nasdaq on the date the Retention Plan was approved by the Compensation Committee. Each option vests in four equal 25% installments on the following dates: (i) June 20, 2018, (ii) December 31, 2018, (iii) June 30, 2019 and (iv) December 31, 2019.

**Agile Therapeutics, Inc.**  
**Notes to Unaudited Financial Statements**  
**September 30, 2019**  
**(in thousands, except share and per share data)**

**10. Restructuring Costs (Continued)**

A summary of accrued restructuring costs, included as a component of accrued liabilities on the Company's unaudited September 30, 2019 balance sheet is as follows:

	<u>December 31, 2018</u>	<u>Charges</u>	<u>Payments</u>	<u>September 30, 2019</u>
2018 Restructuring (severance)	\$ 638	\$ —	\$ (638)	\$ —
Total	<u>\$ 638</u>	<u>\$ —</u>	<u>\$ (638)</u>	<u>\$ —</u>

**11. 2019 Retention Plan**

In July 2019, the Company adopted a retention plan (the "2019 Retention Plan") for all employees (with the exception of the Chairman and Chief Executive Officer) in order to induce such employees to remain employed by the Company through at least the PDUFA goal date of November 16, 2019.

Each employee who participates in the 2019 Retention Plan and remains continuously employed by the Company through the Approval shall be paid a lump-sum cash payment in an amount determined for each eligible employee by the Compensation Committee at the time of the adoption of the 2019 Retention Plan. If an eligible employee terminates employment prior to the Approval for any reason, no such retention payment shall be made to the eligible employee. The total amount of the cash portion of the 2019 Retention Plan is approximately \$0.3 million. Given the uncertainty of the approval of Twirla, the Company has not recorded compensation expense related to these potential cash awards for the period ended September 30, 2019.

All employees (with the exception of the Chairman and Chief Executive Officer) who were employed by the Company as of July 3, 2019 were also granted a stock option to purchase the number of shares of common stock as approved by the Compensation Committee, with a per share exercise price of \$1.48, representing the closing price of the Company's common stock as reported by Nasdaq on the date of grant. Each option will vest in two equal 50% installments on the following dates (i) July 3, 2020 and (ii) December 31, 2020.

In addition, the vesting for the stock options granted in January 2019 have been amended for all employees holding such options who were employed on July 3, 2019 as follows: 50% of the option will vest on January 29, 2020, 25% on June 30, 2020 and the remaining 25% on December 31, 2020.

**12. Commitments and Contingencies**

The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial position. As of September 30, 2019, the Company has not recorded a provision for any contingent losses.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

*The following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (the "SEC") on March 12, 2019. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part 1, Item 1A, "Risk Factors" of our Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Dollars in the text and in tabular format are presented in thousands, except per share data, or as otherwise indicated.*

### Overview

We are a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Twirla® and our other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our short-term goal is to establish a market-leading franchise in the multi-billion-dollar U.S. hormonal contraceptive market built on the planned initial approval of our lead product candidate, Twirla, also known as AG200-15 in the U.S. Twirla is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. We resubmitted our new drug application, or NDA, for Twirla to the U.S. Food and Drug Administration, or FDA, in the second quarter of 2019 and have been assigned a Prescription Drug User Fee Act, or PDUFA, goal date of November 16, 2019.

#### *Recent Regulatory History*

We have had a long and complicated history seeking regulatory approval for Twirla in the U.S., which has included the submission of our NDA for Twirla twice (first in 2012 and again in 2017), the issuance of two complete response letters, or CRLs, from the FDA in 2013 and 2017, and the need to pursue formal dispute resolution with the FDA after the CRL issued in 2017. We expect to face significant challenges as we continue to pursue regulatory approval for Twirla, including an advisory committee review of the safety and efficacy of Twirla, including a discussion regarding the Pearl Index from our SECURE Phase 3 clinical trial that the FDA noted is substantially higher than other previously approved combined hormonal contraceptives, or CHCs. The FDA has notified us that they plan to convene a meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, or BRUDAC, which is the advisory committee for contraceptive products, on October 30, 2019 to discuss the Twirla NDA.

On December 21, 2017, after completion of its review of our Twirla NDA, the FDA, issued the second CRL, or the 2017 CRL. The FDA's reasons for issuing the 2017 CRL related to cited deficiencies in the manufacturing process for Twirla and questions about our clinical *in vivo* adhesion properties. More specifically, the 2017 CRL identifies deficiencies relating to:

- quality control adhesion test methods for the Twirla manufacturing process;
- observations identified during an inspection of a facility of our third-party manufacturer, Corium, for the Twirla NDA that must be resolved; and
- questions on the *in vivo* adhesion properties of Twirla and their potential relationship to the SECURE clinical trial results.

The 2017 CRL also contains recommendations on addressing the cited deficiencies including recommendations that the Company:

- develop manufacturing in-process tests for ensuring the quality and *in vivo* adhesion of the commercial scale product as well as the finished drug specifications and release test method for adhesion;
- assess the *in vivo* adhesion properties demonstrated in the SECURE clinical trial; and

[Table of Contents](#)

- address the implications of clinical trial subject patch compliance and the withdrawal and dropout rates.

In addition, the FDA also identified additional pregnancies, many of which were in women who had delays in applying patches, which they argued should be added to the Pearl Index calculation for Twirla. The FDA expressed concern in the 2017 CRL regarding the implication of delays in patch application for real-world use. The 2017 CRL does not identify any specific issues relating to the safety of Twirla, though the FDA will be considering Twirla’s safety profile in relation to the Phase 3 efficacy results.

At our request, the Division of Bone, Reproductive and Urologic Products, or DBRUP, had a Type A meeting with us on April 16, 2018 to discuss the deficiencies in the Twirla NDA identified in the 2017 CRL and the regulatory path for approval of Twirla. In its official minutes, the FDA informed us that to address concerns surrounding *in vivo* adhesion we needed to reformulate the transdermal system, conduct a formal *in vivo* adhesion study with the new formulation, and demonstrate bioequivalence to the data and information in the original formulation. The FDA also said it anticipates discussing the safety and efficacy of Twirla at an advisory committee meeting to obtain input on whether the benefits of Twirla outweigh the risks. The FDA also provided guidance on the path forward for addressing the manufacturing quality control test method issues related to Twirla, and informed us that whether these issues have been adequately addressed would be subject to review by the FDA when we resubmit our Twirla NDA.

We disagreed with the FDA’s conclusions regarding the *in vivo* adhesion properties of Twirla and the need for product reformulation, and we submitted a formal dispute resolution request, or FDRR, to the FDA. In October 2018, the FDA’s Office of New Drugs, or OND, formally denied our appeal, but provided a path forward for resubmission of the NDA for Twirla that may not require that we reformulate Twirla or conduct a bioequivalence study between formulations, as previously suggested by DBRUP. Specifically, OND suggested that we conduct a wear study to evaluate whether Twirla demonstrates a generally similar adhesion performance to Xulane, the generic version of the previously marketed Ortho Evra® contraceptive patch, a product the FDA considers to have acceptable adhesion. If this result were demonstrated, OND stated that the study would support the conclusion of adequate Twirla adhesion.


As recommended by OND, we met with DBRUP to discuss the specific design and success criteria of the comparative wear study. DBRUP agreed that Twirla would be considered statistically non-inferior to Xulane if the upper 95% confidence limit of the mean difference was less than +0.15. As agreed with DBRUP, we conducted a randomized, open-label, crossover adhesion study in healthy women aged 18 to 35 years with a Body Mass Index of less than 35 kg/m<sup>2</sup>. Subjects were randomized to wear either Twirla or Xulane for the first week and then switched to the patch not initially worn for the second week. The study design followed the 2018 ANDA Guidance for Assessment of Adhesion entitled *Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs*.

On February 11, 2019, we announced the top-line results of the comparative wear study. The study met the non-inferiority criterion set forth by the FDA by demonstrating an upper 95% confidence limit of -0.16.

**Primary endpoint: mean adhesion scores for Twirla and Xulane**

	Twirla		Xulane		Difference (Twirla — Xulane)		
	N	Mean (SD)	N	Mean (SD)	Mean (SD)	One-sided upper 95% CL	Non-inferiority criterion met
Adhesion score in the Per Protocol population	77	0.14 (0.28)	77	0.39 (0.40)	-0.25 (0.23)	-0.16	Yes

### Non-inferiority Scale



We resubmitted our Twirla NDA in the second quarter of 2019. Our resubmission included the results from the comparative wear study, additional information on our manufacturing process, and other analyses responding to the 2017 CRL. Our contract manufacturer, Corium also provided the FDA with responses to each of the observations made during the FDA’s 2017 facility inspection. In addition, we conducted a focused human factors study and a quantitative and qualitative study to assess Twirla’s instructions for use. Based on these studies, we made improvements to the product instructions for use to facilitate the proper use of the patch and reduce application errors.

The FDA recently conducted a pre-approval inspection following our resubmission, and we continue to prepare for an advisory committee meeting. The FDA has informed us that the agency plans to hold a meeting of BRUDAC, which has been scheduled for October 30, 2019, to review of the safety and efficacy of Twirla, where we expect a discussion regarding the Pearl Index, an efficacy measurement from our SECURE Phase 3 clinical trial that the FDA noted is substantially higher than other previously approved CHCs. In advance of the Advisory Committee meeting, the FDA issued its briefing document in which it expresses a number of concerns regarding Twirla’s approvability, including, but not limited to concerns related to Twirla’s efficacy when balanced against its safety. In its briefing materials, the FDA also did not appear to agree with our proposal to include a limitation of use based on patient weight and BMI in the product label.

We can make no assurances that the FDA will agree that the results of the comparative wear study demonstrate adequate adhesion of Twirla. If the FDA determines that Twirla’s adhesion is still inadequate despite the results of the comparative wear study, it will likely not approve the Twirla NDA and require us to reformulate Twirla and conduct additional clinical or bioequivalence studies before we can, again, resubmit the Twirla NDA.

The FDA may also determine that our responses to the manufacturing deficiencies in the 2017 CRL and Corium’s responses to the manufacturing facility inspection observations are not sufficient or require additional analyses and/or studies and deny approval of the Twirla NDA on this basis as well.

#### *Financial Overview*

Since our inception in 1997, we have devoted substantial resources to developing and seeking regulatory approval for Twirla, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. We incurred research and development expenses of \$9.8 million, \$14.4 million and \$20.9 million during the years ended December 31, 2018, 2017 and 2016, respectively. We incurred research and development expenses of \$2.4 million and \$1.5 million for the three months ended September 30, 2019 and 2018, respectively. We incurred research and development expenses of \$7.0 million and \$7.9 million for the nine months ended September 30, 2019 and 2018, respectively. We anticipate that a portion of our operating expenses will continue to be related to research and development as we seek to complete the development of Twirla. Substantially all of our resources are currently dedicated to developing and seeking regulatory approval for Twirla.

We have funded our operations primarily through sales of common stock, convertible preferred stock, convertible promissory notes and term loans. As of September 30, 2019 and December 31, 2018, we had \$18.4 million and \$7.8 million in cash and cash equivalents, respectively.



## [Table of Contents](#)

In August 2019, we completed a public offering of 14,526,315 shares of common stock at a price of \$0.95 per share. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses, were approximately \$12.7 million.

In March 2019, we completed a private placement of 8,426,750 shares of common stock at \$0.93 per share. Proceeds from the private placement, net of offering costs, were approximately \$7.8 million.

In January 2019, we entered into a common stock sales agreement under which we were authorized to sell up to an aggregate of \$10.0 million in gross proceeds through the sale of shares of common stock from time to time in “at-the-market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). We agreed to pay a commission of 3% of the gross proceeds of any common stock sold under this agreement. During the nine months ended September 30, 2019, we issued and sold a total of 1,801,528 shares of common stock under the common stock sales agreement resulting in net proceeds of approximately \$2.5 million. We terminated the common stock agreement on July 31, 2019.

We have not generated any revenue and have never been profitable for any year. Our net loss was \$19.8 million, \$28.3 million and \$28.7 million for the years ended December 31, 2018, 2017 and 2016, respectively. Our net loss was \$4.4 million and \$3.8 million for the three months ended September 30, 2019 and 2018, respectively. Our net loss was \$12.6 million and \$16.0 million for the nine months ended September 30, 2019 and 2018, respectively. We expect to incur increased expenses and increasing operating losses for the foreseeable future as we seek the approval of our NDA for Twirla, which includes preparing for a scheduled FDA advisory committee meeting, completing the qualification and validation of our commercial manufacturing process, initiating pre-launch commercial activities, commercially launching Twirla, if approved, advancing our other potential product candidates and expanding our research and development programs. Substantially all of our resources are currently dedicated to developing and seeking regulatory approval for Twirla. We have halted all further work on our pipeline except for Twirla. We will require additional capital should we choose to advance the development of our other potential product candidates.

### *Commercial Plans*

If we receive approval of the Twirla NDA, we plan to accelerate our commercial activities. In September 2019, we re-started manufacturing development at Corium. We are currently working with Corium to complete manufacturing development and process improvements and plan to commence pre-validation work when that work is complete. Our goal is to manufacture three validation batches of Twirla and complete the validation of the commercial manufacturing process in the second half of 2020.

In parallel, we plan to initiate work with managed care and patient payers to gain market access for Twirla in the first quarter of 2020. In the second quarter of 2020, we plan to hire and train an initial sales team, which we estimate to be in the range of 50 to 90 persons. We expect to ship product to wholesalers and commence our commercial launch in fourth quarter of 2020. Our marketing efforts will initially focus on Obstetrician-gynecologists in the United States, and we plan to use a significant number of samples in the early stage of commercial launch to gain patient trial and acceptance.

We will need to raise additional funds to complete these activities and our ability to complete such activities according to our current planned timelines will depend on our ability to successfully raise the necessary capital. We have structured our commercial plans in a manner that we believe will allow us to either scale-up or down as necessary in the event that the Twirla NDA is not approved or such approval is delayed.

### *Going Concern*

As of September 30, 2019, we had cash and cash equivalents of \$18.4 million. We believe that our cash and cash equivalents as of September 30, 2019, will be sufficient to meet our projected operating requirements through the end of the first quarter 2020. We will require additional capital to fund our operating needs for the rest of 2020 and beyond, which primarily will be used for the completion of our commercial plan for Twirla, if approved, including the completion of the validation of our commercial manufacturing process, the commercial launch, and advancing the development of our other potential product candidates.

Our future success depends on our ability to raise additional capital and/or implement various strategic alternatives. Pursuant to the receipt of the 2017 CRL, and the delay in the approval timeline for Twirla, our ability to continue operations for 2020 and beyond will depend on our ability to obtain additional funding, as to which no assurances can be given. Based upon the foregoing, management has concluded that there is substantial doubt about our ability to continue as a going concern. There can be no assurance that any financing by us can be realized, or if realized, what the terms of any such financing may be, or that any amount that we are able to raise will be adequate.

## [Table of Contents](#)

We continue to analyze strategic and financing alternatives, potential asset sales as well as mergers and acquisitions. We cannot be certain that these initiatives or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to raise funds, whether through the issuance of equity or convertible debt securities, or any combination thereof, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders will experience dilution. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, including Twirla, or grant licenses on terms that may not be favorable to us. If we are unable to obtain funds when needed or on acceptable terms, we then may be unable to complete the development of Twirla, and may also be required to further cut operating costs, forego future development and other opportunities and may need to seek bankruptcy protection.

The unaudited financial statements as of September 30, 2019 have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our ability to continue as a going concern is dependent upon our uncertain ability to obtain additional equity and/or debt financing and reduce expenditures. These unaudited financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We do not own any manufacturing facilities and rely on Corium for all aspects of the manufacturing of Twirla. We will need to continue to invest in the manufacturing process for Twirla, and incur significant expenses, in order to complete the equipment qualification and validation related to the expansion of Corium's manufacturing capabilities in order to be capable of supplying projected commercial quantities of Twirla, if approved. In September 2019, we re-started manufacturing development at Corium. We are currently working with Corium to complete manufacturing development and process improvements and plan to commence pre-validation work when that work is complete. Our goal is to manufacture three validation batches of Twirla and complete the validation of the commercial manufacturing process in the second half of 2020. If we obtain regulatory approval for Twirla, we expect to incur significant expenses in order to create an infrastructure to support the commercialization of Twirla, including sales, marketing, distribution, medical affairs and compliance functions, which will also require additional capital.

We have incurred and will continue to incur additional costs associated with operating as a public company. Accordingly, we will need additional financing to support our continuing operations and other potential product candidates in our pipeline in addition to the commercial activities required for the pre-launch and launch of Twirla, if approved. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise additional capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.

### **Financial Operations Overview**

#### ***Revenue***

To date, we have not generated any revenue. In the future, we may generate revenue from product sales, license fees, milestone payments and royalties from the sale of products developed using our intellectual property. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize Twirla and any product candidates that we may advance in the future. If we fail to complete the development of Twirla or any other potential product candidates we advance in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, will be adversely affected.

#### ***Research and Development Expenses***

Since our inception, we have focused our resources on our research and development activities. Research and development expenses consist primarily of costs incurred for the development of Twirla and other current and future potential product candidates, and include:

## [Table of Contents](#)

- expenses incurred under agreements with contract research organizations, or CROs, and investigative sites that conduct our clinical trials and preclinical studies;
- employee-related expenses, including salaries, benefits, travel and stock-based compensation expenses;
- the cost of acquiring, developing and manufacturing clinical trial materials, including the supply of our product candidates;
- costs associated with research, development and regulatory activities; and
- costs associated with equipment scale-up required for commercial production.

Research and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to us by our third-party vendors.

Research and development activities are central to our business model and to date, our research and development expenses have related primarily to the development of Twirla. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We do not currently utilize a formal time allocation system to capture expenses on a project-by-project basis, as the majority of our past and planned expenses have been and will be in support of Twirla.

For the remainder of 2019, we expect our research and development expenses to increase significantly. Research and development expenses in the fourth quarter of 2019 will consist primarily of continued costs associated with our preparation for an advisory committee meeting, the development and refinement of our commercial manufacturing process and responding to information requests expected to be received from the FDA as part of their review of our NDA resubmission. In anticipation of possible NDA approval, we have recently restarted the final development of our commercial manufacturing process. If we do not receive approval of Twirla in November 2019, we will immediately re-evaluate these activities and scale back or cease if necessary.

For the three months ended September 30, 2019 and 2018, our research and development expenses were approximately \$2.4 million and \$1.5 million, respectively. For the nine months ended September 30, 2019 and 2018, our research and development expenses were approximately \$7.0 million and \$7.9 million, respectively. The following table summarizes our research and development expenses by functional area.

	Three months ended		Nine months ended	
	September 30,		September 30,	
	(In thousands)			
	2019	2018	2019	2018
Clinical development	\$ 66	\$ 160	\$ 1,646	\$ 591
Regulatory	1,321	162	2,012	497
Personnel related	266	501	1,206	1,827
Manufacturing - commercialization	605	403	1,724	3,894
Manufacturing	—	37	20	137
Stock-based compensation	103	286	413	975
Total research and development expenses	\$ 2,361	\$ 1,549	\$ 7,021	\$ 7,921

It is difficult to determine with any certainty the exact duration and completion costs of any of our future clinical trials of Twirla or our other current and future potential product candidates we may advance. It is also difficult to determine if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates that obtain regulatory approval.

## [Table of Contents](#)

Consistent with our previous NDA resubmission in 2017, our resubmission of the NDA responding to the 2017 CRL has been categorized as a Type 2 resubmission and we received a review period of six months from the date of resubmission of the NDA and the FDA assigned a PDUFA goal date of November 16, 2019. We may, however, never succeed in achieving regulatory approval for Twirla or any of our other potential product candidates or such approval may be delayed. The duration, costs and timing of clinical trials and development of our other potential product candidates in addition to Twirla will depend on a variety of factors, including obtaining additional capital, the uncertainties of future clinical trials and preclinical studies, the rate of subject enrollment, and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA, or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, or experience issues with our manufacturing capabilities we could be required to expend significant additional financial resources and time with respect to the development of that product candidate. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential. Substantially all of our resources are currently dedicated to developing and seeking regulatory approval for Twirla. We will require additional capital to fund our operating needs for 2020 and beyond including, among other items, the resumption and completion of our commercial plan for Twirla, which primarily includes the validation of our commercial manufacturing process and the commercial launch of Twirla, if approved, and advancing the development of our other potential product candidates.

### ***General and Administrative Expenses***

General and administrative expenses consist principally of salaries and related costs for personnel in executive, finance and administrative functions including payroll taxes and health insurance, stock-based compensation and travel expenses. Other general and administrative expenses include facility-related costs, insurance and professional fees for legal, patent review, consulting and accounting services. General and administrative expenses are expensed as incurred.

For the three months ended September 30, 2019 and 2018, our general and administrative expenses totaled approximately \$2.1 million and \$1.8 million, respectively. For the nine months ended September 30, 2019 and 2018, our general and administrative expenses totaled approximately \$5.7 million and \$7.2 million, respectively. In January 2018, following our receipt of the 2017 CRL, we significantly scaled back our preparations for commercialization of Twirla, including commercial pre-launch activities, pending our ability to address the 2017 CRL and receive approval of Twirla. If Twirla is approved, we intend to commercialize Twirla in the United States through a direct sales force. We anticipate that our general and administrative expenses will increase in the future in support of our continued research, development and potential commercialization of Twirla, its planned line extensions, and any of our other potential product candidates, and as we operate as a public company. These increases will likely include increased selling and marketing costs, including payroll and operating costs, related to the commercial launch of Twirla, if approved, legal and accounting services, stock registration and printing fees, addition of new personnel to support compliance and communication needs, increased insurance premiums, outside consultants and investor relations. Additionally, if in the future we believe regulatory approval of Twirla or any of our other potential product candidates appears likely, we anticipate that we would begin preparations for commercial operations, which would result in an increase in payroll and other expenses, particularly with respect to the sales and marketing of our product candidates.

### **Critical Accounting Policies and Significant Judgments and Estimates**

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosures. On an ongoing basis, our actual results may differ significantly from our estimates.

[Table of Contents](#)

There have been no material changes to our critical accounting policies and estimates from the information discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K.

**Results of Operations***Comparison of the Three Months Ended September 30, 2019 and 2018*

	Three months ended September 30,		Change
	2019	2018	
Operating expenses:			
Research and development	\$ 2,361	\$ 1,549	\$ 812
General and administrative	2,138	1,767	371
Restructuring costs	—	299	(299)
Total operating expenses	4,499	3,615	884
Other income (expense)			
Interest income	67	91	(24)
Interest expense	—	(268)	268
Change in fair value of warrants	—	—	—
Total other income (expense), net	67	(177)	244
Loss before benefit from income taxes	(4,432)	(3,792)	(640)
Net loss	\$ (4,432)	\$ (3,792)	\$ (640)

**Research and development expenses.** Research and development expenses increased by \$0.8 million, or 52%, from \$1.5 million for the three months ended September 30, 2018 to \$2.4 million for the three months ended September 30, 2019. This increase in research and development expenses was primarily due to the following:

- an increase in regulatory expense of \$1.1 million for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018. This increase is primarily related to consulting fees incurred associated with the resubmission and review of our NDA for Twirla as well as costs associated with the preparation for the upcoming FDA advisory committee meeting;
- an increase in manufacturing commercialization expenses of \$0.2 million for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018. This increase reflects pre-approval inspection (PAI) preparation costs and other NDA related support costs incurred at the Corium manufacturing facility. Costs related to the qualification, validation and manufacture of Twirla will be recorded as research and development expenses until we receive approval of our NDA for Twirla;
- a decrease in personnel-related expenses of \$0.2 million for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018. This decrease is primarily the result of the reduction in workforce that was announced in June 2018 as part of our restructuring efforts;
- a decrease in stock compensation expense of \$0.2 million for the three months ended September 30, 2019 compared to the three months ended September 30, 2018. This decrease is primarily the result of a lower stock price associated with the January 2019 stock option grants as compared to the January 2018 stock option grants; and

## [Table of Contents](#)

- a decrease in clinical development expenses of \$0.1 million for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018. This decrease is primarily related to decreased clinical trial insurance expense.

**General and administrative expenses.** General and administrative expenses increased by \$0.4 million, or 21%, from \$1.8 million for the three months ended September 30, 2018 to \$2.1 million for the three months ended September 30, 2019. This increase in general and administrative expense was primarily due to:

- an increase in professional fee expense of \$0.4 million primarily relates to increased legal activity and use of financial consultants;
- an increase in commercial development expense of \$0.1 million for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018. This increase relates to the resumption of our pre-commercialization activities such as brand building, advocacy, market research and consulting; and
- a decrease in stock compensation expense of \$0.2 million for the three months ended September 30, 2019 compared to the three months ended September 30, 2018. This decrease is primarily the result of a lower stock price associated with the January 2019 stock option grants as compared to the January 2018 stock option grants.

**Restructuring costs.** In June 2018, we announced a reduction in our workforce, which resulted in the termination of several employees primarily from our commercial and clinical teams, representing approximately 30% of our employees. This workforce reduction, along with other reductions in planned operating expenses was designed to preserve cash while we pursued formal dispute resolution with the FDA for Twirla. In addition, in June 2018, we also announced that we had adopted a retention plan to provide (i) cash retention payments to be made to all remaining employees in order to induce such employees to remain employed by the Company through December 31, 2018 and (ii) stock option grants to all remaining employees in order to induce such employees to remain employed by the Company through December 31, 2019. Restructuring costs of \$0.3 million for the three months ended September 30, 2018 represent costs related to the accrual of the retention bonus. All severance-related costs were accrued as of June 30, 2018.

**Interest income.** Interest income comprises interest earned on cash and cash equivalents.

**Interest expense.** Interest expense is primarily attributable to our term loan with Hercules for the three months ended September 30, 2018. Interest expense also included the amortization of the discount associated with allocating value to the common stock warrants issued to Hercules, the amortization of the deferred financing costs associated with the term loan and the accrual of the final payment due to Hercules. Interest expense decreased by \$0.3 million, or 100%, from \$0.3 million for the three months ended September 30, 2018 to \$0 for the three months ended September 30, 2019. The decrease is the result of the completion of the repayment of the term loan with Hercules on December 1, 2018.

*Comparison of the Nine months Ended September 30, 2019 and 2018*

	Nine months ended September 30,		Change
	2019	2018	
<b>Operating expenses:</b>			
Research and development	\$ 7,021	\$ 7,921	\$ (900)
General and administrative	5,732	7,173	(1,441)
Restructuring costs	—	715	(715)
<b>Total operating expenses</b>	<b>12,753</b>	<b>15,809</b>	<b>(3,056)</b>
<b>Other income (expense)</b>			
Interest income	168	289	(121)
Interest expense	—	(955)	955
Change in fair value of warrants	—	29	(29)
<b>Total other income (expense), net</b>	<b>168</b>	<b>(637)</b>	<b>805</b>
Loss before benefit from income taxes	(12,585)	(16,446)	3,861
Benefit from income taxes	—	477	(477)
<b>Net loss</b>	<b>\$ (12,585)</b>	<b>\$ (15,969)</b>	<b>\$ 3,384</b>

**Research and development expenses.** Research and development expenses decreased by \$0.9 million, or 11%, from \$7.9 million for the nine months ended September 30, 2018 to \$7.0 million for the nine months ended September 30, 2019. This decrease in research and development expenses was primarily due to the following:

- a decrease in manufacturing commercialization expenses of \$2.2 million for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018. This decrease reflects reduced activity associated with the scale-up and on-going qualification of the commercial manufacturing equipment primarily as a result of the receipt of the 2017 CRL. Costs related to the qualification, validation and manufacture of Twirla will be recorded as research and development expenses until we receive approval of our NDA for Twirla;
- a decrease in personnel-related expenses of \$0.6 million for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018. This decrease is primarily the result of the reduction in workforce that was announced in June 2018 as part of our restructuring efforts;
- a decrease in stock compensation expense of \$0.6 million for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018. This decrease is primarily the result of a lower stock price associated with the January 2019 stock option grants as compared to the January 2018 stock option grants;
- an increase in regulatory expense of \$1.5 million for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018. This increase is primarily related to consulting fees incurred associated with the resubmission of our NDA for Twirla as well as costs associated with the preparation for the upcoming FDA advisory committee meeting; and

## [Table of Contents](#)

- an increase in clinical development expenses of \$1.0 million for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018. This increase primarily relates to the costs associated with the comparative wear study of Twirla and Xulane which was initiated and completed during the first quarter of 2019.

**General and administrative expenses.** General and administrative expenses decreased by \$1.4 million, or 20%, from \$7.1 million for the nine months ended September 30, 2018 to \$5.7 million for the nine months ended September 30, 2019. This decrease in general and administrative expense was primarily due to:

- a decrease in stock compensation expense of \$0.9 million for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018. This decrease is primarily the result of a lower stock price associated with the January 2019 stock option grants as compared to the January 2018 stock option grants;
- a decrease in personnel-related expenses of \$0.7 million for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018. This decrease is primarily the result of the reduction in workforce that was announced in June 2018 as part of our restructuring efforts;
- a decrease in commercial development expense of \$0.2 million for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018. This decrease relates to the suspension of our pre-commercialization activities such as brand building, advocacy and consulting as a result of the receipt of the 2017 CRL; and
- an increase in professional fee expense of \$0.4 million primarily relates to increased legal activity and use of financial consultants.

**Restructuring costs.** In June 2018, we announced a reduction in our workforce, which resulted in the termination of several employees primarily from our commercial and clinical teams, representing approximately 30% of our employees. This workforce reduction, along with other reductions in planned operating expenses was designed to preserve cash while we pursued formal dispute resolution with the FDA for Twirla. In addition, in June 2018, we also announced that we had adopted a retention plan to provide (i) cash retention payments to be made to all remaining employees in order to induce such employees to remain employed by the Company through December 31, 2018 and (ii) stock option grants to all remaining employees in order to induce such employees to remain employed by the Company through December 31, 2019. Restructuring costs of \$0.7 million for the nine months ended September 30, 2018 represent \$0.4 million of severance-related costs and \$0.3 million of costs related to the accrual of the retention bonus.

**Interest income.** Interest income comprises interest earned on cash and cash equivalents.

**Interest expense.** Interest expense is primarily attributable to our term loan with Hercules for the nine months ended September 30, 2018. Interest expense also includes the amortization of the discount associated with allocating value to the common stock warrants issued to Hercules, the amortization of the deferred financing costs associated with the term loan and the accrual of the final payment due to Hercules. Interest expense decreased by \$1.0 million, or 100%, from \$1.0 million for the nine months ended September 30, 2018 to \$0 for the nine months ended September 30, 2019. The decrease is the result of the completion of the repayment of the term loan with Hercules on December 1, 2018.

**Benefit from income taxes.** For the nine months ended September 30, 2019 and 2018, we received \$0 and \$0.5 million, respectively, from the sale of New Jersey state net operating losses (“NOLs”) as part of the Technology and Business Tax Certificate Program, or the Program. The Program enables approved biotechnology companies to sell their unused Net Operating Loss Carryovers and unused Research and Development Tax Credits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The New Jersey Economic Development Authority and the New Jersey Department of the Treasury’s Division of Taxation administer the Program. We have reached the maximum lifetime benefit of \$15.0 million under the Program and is no longer eligible to participate in the Program.



## Liquidity and Capital Resources

At September 30, 2019, we had cash and cash equivalents totaling \$18.4 million. We invest our cash equivalents in short-term highly liquid, interest-bearing investment-grade and government securities in order to preserve principal.

The following table sets forth the primary sources and uses of cash for the periods indicated:

	Nine Months Ended September 30,	
	2019	2018
Net cash used in operating activities	\$ (12,419)	\$ (13,759)
Net cash used in investing activities	(30)	(318)
Net cash provided by (used in) financing activities	22,968	(4,949)
Net increase (decrease) in cash and cash equivalents	<u>\$ 10,519</u>	<u>\$ (19,026)</u>

### Operating Activities

We have incurred significant costs in the area of research and development, including CRO fees, manufacturing, regulatory and other clinical trial costs, as our lead product candidate, Twirla, was being developed. Net cash used in operating activities was \$12.4 million for the nine months ended September 30, 2019 and consisted primarily of a net loss of \$12.6 million, offset by non-cash stock-based compensation expense of \$1.3 million. Net cash used in operating activities was \$13.8 million for the nine months ended September 30, 2018 and consisted primarily of a net loss of \$16.0 million, which was offset by non-cash stock-based compensation expense of \$2.8 million and non-cash interest expense of \$0.4 million. Cash used in operations for the nine months ended September 30, 2018 was offset, in part, by the proceeds received from the sale of New Jersey NOLs. The decreased clinical development expenses were offset by increased commercial development and commercial manufacturing expenses related to the initialization of pre-commercialization activities for Twirla.

### Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2019 and 2018 was \$0 and \$0.3 million, respectively. Cash used in investing activities for the nine months ended September 30, 2018 primarily represents the acquisition of equipment to be used in the commercialization of Twirla, if approved.

### Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2019 was \$23.0 million which primarily represented net proceeds of \$7.8 million received from the issuance of 8,426,750 shares of our common stock in a private placement, net proceeds of \$12.7 million from the sale of 14,526,315 shares of common stock through a public offering, and net proceeds of approximately \$2.5 million from the sale of a total of 1,801,528 shares of our common stock through an at-the-market, or ATM, sales program. Net cash used in financing activities for the nine months ended September 30, 2018 was \$4.9 million, which primarily represented principal payments under the Hercules loan agreement, which began on February 1, 2017.

### Funding Requirements and Other Liquidity Matters

Since 2012, we have sought regulatory approval for Twirla and, in the process, received two complete response letters from the FDA in connection with our NDA for Twirla, which have included requests to conduct additional studies and gather additional information on our manufacturing process for Twirla. In January 2018, in response to the 2017 CRL, we significantly scaled back equipment qualification and validation of our commercial manufacturing process and our other commercial pre-launch activities. Since then we have engaged with the FDA to seek clarity on a regulatory path for the potential approval of Twirla culminating in a formal dispute resolution request to the FDA, which was completed in October 2018.

We resubmitted our Twirla NDA responding to the 2017 CRL in the second quarter of 2019. Consistent with our previous NDA resubmission in 2017, our resubmission has been categorized as a Type 2 resubmission and we

## [Table of Contents](#)

received a review period of six months from the NDA resubmission date with an assigned PDUFA goal date of November 16, 2019. The FDA has informed us that in connection with the review of the Twirla NDA, the FDA plans to bring the issue of Twirla's safety and efficacy to BRUDAC, which has been scheduled for October 30, 2019.

In addition to the reductions in planned operating expenses we began implementing in January 2018, we reduced our workforce by approximately thirty percent in June 2018 as we pursued formal dispute resolution and a path forward for the resubmission of our NDA for Twirla.

We believe that our cash and cash equivalents as of September 30, 2019, will be sufficient to meet our projected operating requirements through the end of the first quarter 2020. We will require additional capital to fund our operating needs for the rest of 2020 and beyond, which primarily will be used for the completion of our commercial plan for Twirla, if approved, including the completion of the validation of our commercial manufacturing process, the commercial launch, and advancing the development of our other potential product candidates. We cannot assure you that the FDA will approve Twirla, or that we along with Corium, our third-party manufacturer, will be able to complete validation of our commercial manufacturing successfully and in a timely manner.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

- prepare for and participate in the review of the safety and efficacy of Twirla at a meeting of BRUDAC;
- seek marketing approval for Twirla in the United States;
- establish a sales and marketing infrastructure to commercialize Twirla in the United States, if approved;
- complete the equipment qualification and validation related to the expansion of Corium's manufacturing facility in preparation for potential commercial operations;
- continue to evaluate additional line extensions for Twirla and initiate development of potential product candidates in addition to Twirla;
- maintain, leverage and expand our intellectual property portfolio; and
- add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts.

We may also need to raise additional funds sooner if we choose to accelerate components of our commercial plan or we encounter any unforeseen events that affect our current business plan or we may choose to raise additional funds to provide us with additional working capital. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed or on attractive terms or are unable to enter into strategic collaborations, we then may be unable to complete the development of Twirla and may also be required to further cut operating costs, forgo future development and other opportunities or even terminate our operations, which may involve seeking bankruptcy protection. Because of the numerous risks and uncertainties associated with the development of Twirla, including, among other things, manufacturing scale up, FDA review of the NDA for Twirla and commercialization of Twirla, if approved, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of Twirla. Our future capital requirements will depend on many factors, including:

- the costs, timing and outcome of regulatory review of Twirla;
- the costs of the equipment qualification and validation related to the expansion of Corium's manufacturing facility in preparation for potential commercial operations;

## [Table of Contents](#)

- the costs of future commercialization activities, including the commercial launch, product sales, marketing, manufacturing and distribution, for Twirla, if approved;
- the revenue, if any, received from commercial sales of Twirla, if approved;
- the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and
- the costs associated with any potential business or product acquisitions, strategic collaborations, licensing agreements or other arrangements that we may establish.

We do not have any committed external source of funds. Until such time, if ever, as we can generate substantial cash flows from product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.

### *Going Concern*

Pursuant to the receipt of the 2017 CRL, and the delay in the approval timeline for Twirla, our ability to continue operations for 2020 and beyond will depend on our ability to obtain additional funding, as to which no assurances can be given. Based upon the foregoing, management has concluded that there is substantial doubt about our ability to continue as a going concern. There can be no assurance that any financing by us can be realized, or if realized, what the terms of any such financing may be, or that any amount that we are able to raise will be adequate.

As of September 30, 2019, we had cash and cash equivalents of \$18.4 million. Our future success depends on our ability to raise additional capital and/or implement various strategic alternatives. We continue to analyze strategic and financing alternatives, potential asset sales as well as mergers and acquisitions. We cannot be certain that these initiatives or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to raise funds, whether through the issuance of equity or convertible debt securities, or any combination thereof, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current shareholders may experience dilution. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, including Twirla, or grant licenses on terms that may not be favorable to us. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current development programs, cut operating costs, forego future development and other opportunities and may need to seek bankruptcy protection.

The unaudited financial statements as of September 30, 2019 have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our ability to continue as a going concern is dependent upon our uncertain ability to obtain additional equity and/or debt financing and reduce expenditures. These unaudited financial statements do not include any adjustments that might result from the outcome of this uncertainty.

[Table of Contents](#)

**Contractual Obligations and Commitments**

The following table summarizes our contractual obligations and commitments as of September 30, 2019 that will affect our future liquidity:

	<u>Total</u>	<u>Less than 1 year</u>	<u>1 - 3 years</u>	<u>3 - 5 years</u>	<u>More than 5 years</u>
Operating Lease	\$ 241	\$ 206	\$ 35	\$ —	\$ —
Total	<u>\$ 241</u>	<u>\$ 206</u>	<u>\$ 35</u>	<u>\$ —</u>	<u>\$ —</u>

Our operating lease commitment relates to our lease of office space in Princeton, New Jersey. In August 2015, we renewed this lease with the new term to expire in November 2020.

**Shelf Registration Statement**

On June 30, 2018, the shelf registration statement we filed on June 19, 2015, which we refer to as the 2015 Shelf Registration Statement, expired. On November 2, 2018, we filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate amount of \$100.0 million, which we refer to as the 2018 Shelf Registration Statement. On November 14, 2018, the 2018 Shelf Registration Statement was declared effective by the SEC.

On January 23, 2019, we filed a prospectus supplement to our 2018 Shelf Registration Statement registering an at-the-market offering program we entered into for the sale of up to \$10.0 million of shares of our common stock. During the nine months ended September 30, 2019, we sold a total of 1,801,528 shares of our common stock under the ATM program resulting in net proceeds of approximately \$2.5 million. We terminated this at-the-market offering program on July 31, 2019.

In August 2019, we filed a prospectus supplement to our 2018 Shelf Registration Statement registering a public offering of 14,526,315 shares of common stock at a price of \$0.95 per share. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses, were approximately \$12.7 million.

**Recent Accounting Pronouncements**

See Note 2 to our financial statements that discusses new accounting pronouncements.

**Off-Balance Sheet Arrangements**

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

*Interest Rate Risk*

We are exposed to market risks in the ordinary course of our business. Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, financing, exchange rates or other factors. These market risks are principally limited to interest rate fluctuations.

## [Table of Contents](#)

We had cash and cash equivalents of \$18.4 million and \$7.8 million at September 30, 2019 and December 31, 2018, respectively consisting primarily of funds in cash and money market accounts. The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly increasing risk. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio, we do not believe an immediate 10.0% increase in interest rates would have a material effect on the fair market value of our portfolio, and accordingly we do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.

Our results of operations and cash flows are subject to fluctuations due to changes in interest rates. We do not believe that we are materially exposed to changes in interest rates. We do not currently use interest rate derivative instruments to manage exposure to interest rate changes. We estimate that a 1% unfavorable change in interest rates would not have a material effect on interest expense for the year ended December 31, 2019.

### *Inflation Risk*

Inflation generally affects us by increasing our cost of labor and pricing of contracts and agreements. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during the three and nine months ended September 30, 2019.

## **Item 4. Controls and Procedures.**

### *Disclosure Controls and Procedures*

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

### *Changes to Internal Controls Over Financial Reporting*

There has been no change in internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting.

## **Part II: Other Information**

### **Item 1. Legal Proceedings.**

We are not currently subject to any material legal proceedings.

### **Item 1A. Risk Factors.**

The following updated risk factors should be considered in addition to our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2018:

## Risks Related to the Regulatory Approval for Our Product Candidates

*We have not obtained regulatory approval for any of our product candidates in the United States or any other country, and such approval or approvals may never be granted or may be substantially delayed if regulatory authorities require additional time or studies to assess the safety and efficacy of our product candidates.*

We currently do not have any product candidates that have gained regulatory approval for sale in the United States or any other country, and we cannot guarantee that we will ever have marketable products. Our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully commercialize product candidates in a timely manner. We cannot commercialize product candidates in the United States without first obtaining regulatory approval to market each product candidate from the FDA; similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. We are not currently pursuing any regulatory approvals for Twirla or any other potential product candidate outside the United States.

Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate in, or rely on data from, preclinical studies and well-controlled clinical trials and, with respect to approval in the United States, to the satisfaction of the FDA, that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. In the United States, it is necessary to submit an NDA to obtain FDA approval. An NDA must include extensive preclinical and clinical data and supporting information to establish the product candidate's safety and efficacy for each desired indication, although we may partially rely on published scientific literature or the FDA's prior approval of similar products. The NDA must also include significant information regarding the chemistry, manufacturing and controls, or CMC, for the product. The FDA may further inspect our manufacturing facilities to ensure that the facilities can manufacture our product candidates and our products, if and when approved, in compliance with the applicable regulatory requirements, as well as inspect our clinical trial sites to ensure that our studies are properly conducted. Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. Upon submission, or resubmission, of an NDA, the FDA must make an initial determination that the application is sufficiently complete to accept the submission for filing. We cannot be certain that any submissions we might make will be accepted for filing and review by the FDA, or ultimately be approved.

If the application is not approved, the FDA may require that we conduct additional clinical or preclinical trials, reformulate the product, address issues with our manufacturing process or facilities, or take other actions before it will reconsider our application. If the FDA requires additional studies or data, or if the FDA determines that our comparative wear study of Twirla and Xulane does not support the conclusion of adequate Twirla adhesion and requires us to reformulate Twirla before resubmitting the Twirla NDA, or if the FDA, an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval, we may never receive marketing approval or we would incur delays in the marketing approval process and increased costs, which may require us to expend more resources than we have available. Studies required to demonstrate the safety and efficacy of our product candidates are time consuming, expensive and together take several years or more to complete, and approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions and could lead to additional costs and delays. In addition, the FDA may not consider any additional information to be complete or sufficient to support approval.

For instance, we have had a long and complicated history seeking regulatory approval for Twirla in the U.S., which has included the submission of our NDA for Twirla twice (first in 2012 and again in 2017), the issuance of two complete response letters, or CRLs, from the FDA in 2013 and 2017, and the need to pursue formal dispute resolution with the FDA after the 2017 CRL. We expect to face significant challenges as we continue to pursue regulatory approval of Twirla, including the Advisory Committee review of the safety and efficacy of Twirla, including an efficacy measurement from our SECURE Phase 3 clinical trial that FDA noted is substantially higher than other previously approved combined hormonal contraceptives

## [Table of Contents](#)

There is no guarantee that the data obtained from the SECURE clinical trial, our comparative wear study, or any other clinical trial, or our changes to the manufacturing testing process and specifications to address the 2017 CRL's findings will be supportive of, or guarantee, or result in our successfully obtaining timely FDA approval of Twirla for a commercially viable indication, if at all. We resubmitted our NDA for Twirla with the clinical data from the SECURE clinical trial, our comparative wear study, and additional information and analyses responding to the 2017 CRL in the second quarter of 2019. FDA could determine that the trial did not meet its objectives, or the FDA could still have concerns about the conduct of the SECURE clinical trial, including regarding discontinuance of subjects from the trial, the rate of unscheduled bleeding, and subject delays in patch application, which were factors mentioned in the 2017 CRL. While we designed the protocol for the SECURE clinical trial in consultation with the FDA after the 2013 CRL, and completed analyses and other requested items to address the issues raised in the 2013 and 2017 CRLs, there is no guarantee that the FDA will deem such steps to be sufficient to address those issues when they are formally reviewed as a part of an NDA resubmission or to demonstrate safety and efficacy to the satisfaction of the FDA. The FDA may also find that our manufacturing testing and specification changes do not address its CRL findings.

In addition to a review of the safety and efficacy of Twirla, the FDA must determine that Corium's manufacturing facilities meet certain FDA requirements for product manufacturing, before granting product approval and before we can use them in the commercial manufacture of our products. We cannot assure you that Corium's responses and actions to rectify to the objectionable conditions found during the FDA's facility inspection will adequately address the issues communicated by the FDA in the 2017 CRL. The FDA may also determine that our responses to the deficiencies in the 2017 CRL and Corium's responses to the manufacturing facility inspection objectionable conditions are not sufficient or require product development and additional analyses and/or studies and deny approval of the Twirla NDA on this basis as well. If the FDA does not approve the Corium facility for the manufacture of Twirla, or if Corium is not able to address the objectionable conditions found by the FDA, or if the FDA finds other objectionable conditions at Corium, the FDA could withhold approval or we may need to find an alternative supplier, which will take time and monetary expenditures, and which we may not be able to do on favorable terms to us or at all.

We resubmitted our Twirla NDA in the second quarter of 2019. Consistent with our previous NDA resubmission in 2017, the 2019 resubmission was categorized as a Type 2 resubmission and received a review period of six months from the date of resubmission of the NDA. There can be no assurance that we will address the outstanding FDA questions in a manner sufficient for approval in the U.S.

In addition to the factors discussed above, delays in regulatory approvals or rejections of applications for regulatory approval in the United States, or any other markets may result from many other factors, including:

- Lack of adequate funding to commence or continue our clinical trials due to unforeseen costs or other business decisions;
- Our inability to obtain sufficient funds required to complete clinical development, manufacturing development or regulatory review processes;
- Regulatory requests for additional analyses, reports, data, non-clinical and preclinical studies and clinical trials;
- Our inability to adequately address the cited deficiencies in the 2017 CRL;
- A government shutdown delays or constrains the FDA's ability to complete NDA reviews according to PDUFA timelines;
- Regulatory requests for additional product design work and testing;
- Regulatory questions regarding interpretations of data and results and the emergence of new information regarding our product candidates or other products;
- Regulators may not agree with our analyses or proposals, may interpret our data and study results differently than we do, or may not find our study results supportive of approval.;
- Clinical holds, other regulatory objections to commencing or continuing a clinical trial or the inability to obtain regulatory approval to commence a clinical trial in countries that require such approvals;

## [Table of Contents](#)

- Failure to reach agreement with the FDA or non-U.S. regulators regarding the scope or design of our clinical trials;
- Unfavorable or inconclusive results of clinical trials and supportive nonclinical studies, including unfavorable results regarding safety or efficacy of our product candidates during clinical trials;
- Any determination that a product candidate presents an unacceptable health risk or that the product candidate's risks are not sufficiently outweighed by associated benefits;
- Corium's inability to adequately resolve the objectionable conditions observed by the FDA when inspecting the facility or our inability to find an alternative supplier;
- Our inability to obtain approval for the manufacturing processes or Corium's facilities with whom we contract for clinical and commercial supplies;
- An FDA determination that our statistical analyses are not sufficient to support approval;
- Failure of manufacturers to comply with FDA's or comparable regulatory authorities' requirements for the manufacture of products and product candidates;
- FDA or comparable regulatory authority determinations that our manufacturing processes, specifications, or tests are not sufficient or acceptable;
- FDA or comparable regulatory authority determinations that our clinical trials were not properly conducted or that such conduct did not comply with regulatory requirements;
- Our inability to obtain agreement from the FDA on product labeling; and
- insufficient funds to pay the significant user fees required by the FDA upon the filing of any future NDAs.

***On October 30, 2019, the FDA will be convening a meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee to discuss the Twirla NDA. The outcome of this meeting is uncertain and an adverse advisory committee opinion would likely negatively impact our ability to receive FDA approval of the Twirla NDA. Moreover, a favorable advisory committee opinion may not result in the receipt of FDA approval for Twirla.***

On October 30, 2019, the FDA will be convening a meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee to discuss the Twirla NDA. Based on prior comments received from the FDA, we expect that the Advisory Committee review will primarily focus on Twirla's efficacy when weighed against the FDA's view of the product candidate's safety profile.

Based on the FDA's Advisory Committee Briefing Document, the FDA has expressed significant concerns regarding Twirla's approvability. By example, the FDA noted that the Twirla Pearl Index is substantially higher than other previously approved combined hormonal contraceptives and stated that it is concerned that Twirla is not adequately effective in the general population of women in the U.S., as well as in non-obese women. For this and other reasons, it does not appear the FDA agrees with our proposal to include a limitation of use based on patient weight and BMI in the product label. The FDA also discussed its view that Twirla is not a "low-dose" contraceptive, does not address an unmet need, and does not appear to demonstrate a safety advantage over other combined hormonal contraceptives. By example, the FDA stated that it does not believe that levonorgestrel-containing products are safer than combined hormonal contraceptives containing newer generation progestins. The FDA also stated that there is considerable uncertainty about the magnitude of venous thromboembolism risk associated with Twirla and how that risk compares to other combined hormonal contraceptive products. This conclusion may ultimately impact the FDA's risk/benefit analysis of the product candidate as the FDA believes that a high level of efficacy in preventing pregnancy must be demonstrated to justify the risks associated with combined hormonal contraceptives. The FDA further stated that it does not agree that the SECURE study results are attributable to the study's design and population, and that the SECURE study does not reflect real-world use. Moreover, the FDA noted that the SECURE study results relating to cycle control, discontinuation rates, and patch adhesion raise questions regarding potential patient compliance, and patch usability and tolerability.

Typically, Advisory Committees will provide responses to specific questions asked by the FDA, including the committee's view on the approvability of the product candidate under review. Advisory Committee decisions are not binding, but an adverse decision at the Advisory Committee may have a negative impact on the regulatory



[Table of Contents](#)

review of Twirla. The Advisory Committee may recommend non-approval for Twirla or may recommend approval with label restrictions. Even if the Advisory Committee determines that the benefits of Twirla outweigh its risks and recommends approval, the FDA could still conclude that the Pearl Index is too high to demonstrate efficacy and an adequate risk/benefit profile for either the overall study population or a subgroup of the study population. Accordingly, the FDA may not approve the Twirla NDA. Alternatively, the FDA may determine that for a specific subgroup of patients, Twirla has lower efficacy and presents a higher risk, necessitating labeling restrictions, statements or warnings. For instance, the FDA may require labeling restrictions, statements or warnings on the use of Twirla for patients in certain BMI categories. We may also need to implement risk management strategies to educate health care providers and patients on any risks or limitations associated with our products, if approved, and to potentially improve patient compliance. The FDA may also ask us to conduct additional clinical studies or perform additional work to address questions that arise as a result of the FDA's review of the Twirla NDA or the outcome of the Advisory Committee meeting. Failure to receive approval or significant additional delay in obtaining a decision from FDA, on whether to approve our NDA for Twirla would have a material adverse effect on our business and results of operations, including possible termination of Twirla development and restructuring of our organization, which could include reducing, or even terminating, our operations. Even if Twirla is approved, the labeling approved by the FDA and any other post-approval obligations that the FDA may require, may restrict how and to whom we and our potential partners, if any, may market the product or the manner in which our product may be administered and sold, which could significantly limit the commercial opportunity for Twirla.

**Item 6. Exhibits.**

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description of Document</b>
10.1	<a href="#">Employment Agreement dated July 16, 2019 by and between the Registrant and Dennis P. Reilly</a>
31.1	<a href="#">Certification of the Registrant's Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2	<a href="#">Certification of the Registrant's Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1*	<a href="#">Certification of the Registrant's Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
32.2*	<a href="#">Certification of the Registrant's Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101	Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders' Equity, (v) Statements of Cash Flows, and (vi) the Notes to Financial Statements.

\* The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report and will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 28, 2019

Agile Therapeutics, Inc.

By: /s/ Alfred Altomari  
Alfred Altomari  
President and Chief Executive Officer  
(Principal Executive Officer)

Date: October 28, 2019

By: /s/ Dennis P. Reilly  
Dennis P. Reilly  
Vice President and Chief Financial Officer  
(Principal Financial and Accounting Officer)

**EMPLOYMENT AGREEMENT**

**THIS EMPLOYMENT AGREEMENT** (this "Agreement") is entered into as of August 5, 2019, by and between AGILE THERAPEUTICS, INC., a Delaware corporation (the "Company"), and Dennis P. Reilly (the "Executive"), collectively referred to as the "parties."

**Recitals:**

The Company desires to continue to employ the Executive and to have the benefit of the Executive's skills and services, and the Executive desires to accept such employment with the Company, on the terms and conditions set forth herein.

In consideration of the mutual promises, covenants, and conditions set forth in this Agreement, the parties agree as follows:

**SECTION 1. EMPLOYMENT**

**a. Position.** The Company wishes to employ the Executive as Chief Financial Officer of the Company reporting to the Chairman and Chief Executive Officer of the Company, and the Executive hereby agrees to continue in such position for the term of this Agreement and to perform those duties and responsibilities as shall be assigned to the Executive by the Board of Directors of the Company (the "Board") or its designee and that are consistent with the Executive's position.

**b. The Executive's Commitment.** The Executive shall consider the Executive's employment by the Company as the Executive's principal employment, shall devote the Executive's necessary time and attention to the Executive's duties and responsibilities under this Agreement, and shall perform the Executive's duties and responsibilities to the best of the Executive's abilities. While subject to any provision of this Agreement, the Executive shall maintain loyalty to the Company and shall take no action that would directly or indirectly promote any competitor or injure the Company's interests. Subject to the foregoing, the Executive may engage in other business activities to the extent that they do not interfere with the Executive's obligations under this Agreement, provided that each of those activities is first disclosed to and approved by the Board. Schedule A to this Agreement contains a list of the other business activities in which the Executive is currently engaged and, to the extent applicable, the dates by which certain of those activities will be terminated.

**SECTION 2. TERMINATION OF EMPLOYMENT**

**a. Term.** The Executive's employment with the Company shall commence on the date hereof and shall continue until terminated in accordance with Section 2b, 2c, 2d, or 2e hereof.

---

**b. Termination for "Reasonable Cause."** The Executive's employment may be terminated by the Company at any time, without prior notice, upon a showing of "Reasonable Cause," as defined below. Should the Executive's employment be terminated by the Company for "Reasonable Cause," no severance or other unearned compensation shall be payable by the Company to the Executive nor shall the Company be obligated to continue to provide to the Executive at the Company's expense, or reimburse the Executive for, any health insurance benefits after the effective date of the termination. "Reasonable Cause" shall be defined for the purposes of this Agreement as being any of the following:

(i) any act or omission by the Executive that reasonably constitutes dishonesty, disloyalty, fraud, deceit, gross negligence, willful misconduct, or recklessness, including, but not limited to the Executive's willful violation of the Company's bylaws or code of regulations, and that is directly or indirectly materially detrimental to the Company's best interest;

(ii) the Executive's intentional failure to perform any lawful duties assigned to the Executive by the Board or its designee after receiving notice and a reasonable opportunity to cure;

(iii) the commission of any act by the Executive that constitutes a felony under the laws of the United States or the state of the Company's principal place of business; and

(iv) any material breach by the Executive of Section 5, 6, 7, or 8 of this Agreement.

Furthermore, the termination by the Executive of the Executive's employment with the Company for any reason other than for Good Reason pursuant to Section 2d shall be deemed to be a termination of the Executive's employment for "Reasonable Cause" without any notice or other action on the part of the Company.

**c. Death or Disability.** The Executive's employment shall terminate immediately upon the Executive's death. The Executive's employment shall terminate immediately upon disability of the Executive to the extent consistent with applicable law. For purposes of this Agreement, the Executive shall be deemed to have a "disability" if, in the reasonable opinion of the Board, the Executive is unable to perform the essential functions of the Executive's job, with or without reasonable accommodation(s), for at least ninety (90) consecutive days because of illness, incapacity, or physical or mental disability, and the Executive's inability to do so perform poses an undue hardship for the Company.

**d. Termination by the Executive for Good Reason.** The Executive may resign from employment with the Company for Good Reason, but only in accordance with the terms of this Section 2d. "Good Reason" shall be deemed to exist with respect to any termination by the Executive of the Executive's employment for any of the following reasons: (i) the relocation of the office of the Company at which the Executive is principally employed to a location that is more than fifty (50) miles from the location of such office as of the date of this Agreement; (ii) any failure by the Company to comply with any material term of this Agreement; or (iii) the demotion of the Executive to a lesser position than described in Section 1a hereof or a substantial

diminution of the Executive's authority, duties, or responsibilities as in effect on the date of this Agreement or as may be hereafter increased; provided, however, that "Good Reason" shall not include a termination of the Executive's employment pursuant to Sections 2b or 2c hereof or, following a Change of Control (as defined in Section 4d below), a reduction in title, position, responsibilities, or duties solely by virtue of the Company being acquired and made part of, or operated as a subsidiary of, a larger company or organization, so long as such new duties and responsibilities are reasonably commensurate with the Executive's experience.

The Executive may not resign with Good Reason pursuant to this Section 2d, and shall not be considered to have done so for any purpose of this Agreement, unless (i) the Executive, within sixty (60) days after the initial existence of the act or failure to act by the Company that constitutes "Good Reason" within the meaning of this Agreement, provides the Company with written notice that describes, in particular detail, the act or failure to act that the Executive believes to constitute "Good Reason" and identifies the particular clause of this Section 2d that the Executive contends is applicable to such act or failure to act; (ii) the Company, within thirty (30) days after its receipt of such notice, fails or refuses to rescind such act or remedy such failure to act so as to eliminate "Good Reason" for the termination by the Executive of the Executive's employment relationship with the Company, and (iii) the Executive actually resigns from employment with the Company on or before that date that is six (6) calendar months after the initial existence of the act or failure to act by the Company that constitutes "Good Reason." If the requirements of the preceding sentence are not fully satisfied on a timely basis, then the resignation by the Executive from the Executive's employment with the Company shall not be deemed to have been for "Good Reason," the Executive shall not be entitled to any of the benefits to which the Executive would have been entitled if the Executive had resigned from employment with the Company for "Good Reason," and the Company shall not be required to pay any amount that would otherwise have been due to the Executive under Section 4a had the Executive resigned with "Good Reason."

e. **Other Termination.** The Executive's employment may also be terminated by the Company for any reason other than as set forth in Section 2b, 2c, or 2d.

### SECTION 3. COMPENSATION, BENEFITS AND EXPENSES

a. **Salary.** The Company shall pay the Executive an annual base salary at the rate of \$350,000 (the "Base Salary"), payable in accordance with the Company's payroll practices in effect from time to time.

b. **Bonus.** The Executive shall be eligible to receive an annual bonus ("Annual Bonus"). The Executive's Annual Bonus Target shall be 40% of the Executive's Base Salary. Whether the bonus will be awarded to the Executive and the amount of the annual bonus shall be determined by the Board or its Compensation Committee based upon achievement of such goals that shall be established by the Board. The bonus, if awarded to the Executive, shall be paid within two and one-half (2 1/2) months after the close of each fiscal year. The Annual Bonus for 2019, if any, will be pro-rated based on the number of full days of service with the Company in 2019 from the commencement date of the Executive's employment until December 31, 2019.

**c. Equity Program.** The Executive shall be eligible to participate in equity incentive programs established by the Company from time to time in the future to provide stock options and other equity-based incentives to key employees of the Company. All such stock options and other equity-based incentives shall be awarded in the discretion of the Board pursuant to the terms of the Company's 2014 Amended and Restated Incentive Compensation Plan and/or such other plans as shall from time to time be established by the Company (the "Equity Plan"). Subject to the approval of the Board of Directors or its Compensation Committee, the Executive will be granted an initial stock option under the Company's Equity Plan exercisable for the purchase of 150,000 shares of the Company's common stock. The per-share exercise price of the stock option will be equal to the fair market value of a share of the Company's common stock at the closing price at the end of the day on the date of grant, which will be the date of the Executive's first day of employment with the Company. The stock option will vest as follows, provided that the Executive continues to be employed by the Company on each respective vesting date: 25% on the first anniversary date of the commencement date of the Executive's employment, and the balance in 36 substantially equal monthly installments beginning in the thirteenth month after the commencement date of the Executive's employment, and vesting will accelerate upon a Change of Control of the Company (as defined in the Equity Plan). The stock option will be subject to the terms of the Equity Plan and a stock option agreement to be executed by the Executive as a condition to the grant.

**d. Health and Long-Term Disability Insurance.** The Executive shall be entitled to participate in such employee benefit plans (collectively the "Plans") as are implemented by the Company and available to executive officers of the Company. The Company shall have the right, from time to time and in its sole discretion, to modify and amend the Plans and benefits provided to its executive officers and other employees, including the Executive. In addition to any key man insurance taken out by the Company, and provided that the Executive can pass the required physical examinations, during the term of this Agreement the Company shall, at its election, either provide to the Executive or reimburse the Executive for the premiums for term life insurance in an amount equal to two times the sum of the Executive's Base Salary plus target Annual Bonus, up to \$1,000,000, with Executive designating the beneficiary of such policy.

**e. Vacation.** The Executive shall be entitled to four (4) weeks paid vacation per year during the term of the Executive's employment pursuant to this Agreement, provided that such vacation shall be taken at times mutually agreeable to the Executive and the Company and otherwise pursuant to applicable workplace policies governing the use of vacation. Vacation shall be administered according to the applicable policies of the Company.

**f. Effect of Termination on Salary and Benefits.** The Executive's Base Salary and benefits under this Section 3 shall terminate effective immediately on the date of the termination of the Executive's employment by the Company, and from that date the Executive shall be entitled to severance benefits under Section 4 if and only to the extent such benefits are then payable in accordance with the terms and provisions of this Agreement.

**g. Effect of Termination on Other Provisions.** This Agreement shall continue in effect upon and after the termination of the Executive's employment for any reason necessary to enforce the provisions of this Agreement that apply subsequent to any such termination,

including any provisions relating to confidentiality, invention assignment, non-solicitation, and non-competition.

**h. Expense Reimbursement.** The Company shall reimburse the Executive for all reasonable out-of-pocket expenses incurred in connection with the Company's business and the Executive's performance of the Executive's obligations under this Agreement, in accordance with the applicable expense reimbursement policy of the Company, upon submission by the Executive to the Company of such written evidence of such expense as the Company may require. Any disputes as to the eligibility of an expense for reimbursement shall be resolved in the sole discretion of the Company.

**i. Housing Allowance.** During the period of August 5, 2019 to December 31, 2019, the Company will pay the Executive a housing allowance of \$5,000 (less any applicable withholding taxes) per calendar month. The housing allowance be paid no later than the 5<sup>th</sup> day of each calendar month.

**j. Recovery of Incentive Compensation.** Notwithstanding anything herein to the contrary, the Executive agrees that all incentive compensation, including cash and equity awards payable to the Executive under this Agreement or otherwise, shall be subject to any clawback policy adopted or implemented by the Board and all other applicable Company policies, consistent with applicable law.

#### **SECTION 4. PAYMENTS AND BENEFITS UPON TERMINATION**

**a. Payments and Benefits upon Termination.** Subject to the satisfaction of the terms of Section 4b, if during the term of this Agreement (i) the Executive's employment under this Agreement is terminated by the Company pursuant to Section 2e (i.e., other than a termination for Reasonable Cause pursuant to Section 2b or a termination upon death or disability pursuant to Section 2c), or the Executive resigns from employment with the Company with Good Reason pursuant to Section 2d (each a "Qualifying Termination"), or (ii) the Executive's employment under this Agreement terminates due to the Executive's disability pursuant to Section 2c, the Executive shall be entitled to receive from the Company the benefits set forth in subsection (i), (ii), or (iii) below, as applicable.

(i) *Qualifying Termination Not in Connection with a Change of Control* If the Qualifying Termination occurs prior to the effective date of a Change of Control, or the Qualifying Termination occurs more than 12 months after a Change of Control, the Executive shall be entitled to:

A. continuation of the Executive's Base Salary (at the salary rate then in effect) for six (6) months if the Qualifying Termination occurs prior to February 3, 2020, after which the Executive shall vest an additional 1 month of salary continuation for each additional month served through July 31, 2020 after which time the Executive shall be entitled to twelve (12) months salary continuation (the "Severance Period"), in accordance with the Company's payroll schedule, commencing on the sixtieth (60th) day after the Executive's effective date of termination, with the first such installment payment including any unpaid severance payments

that would have been made on the normal payroll dates occurring during the first sixty (60) days following the date of termination, provided that if there is a Change of Control before all of the payments under this subsection (A) have been paid, such remaining payments shall be accelerated and paid in a lump sum within sixty (60) days following the Change of Control to the extent permitted by section 409A of the Internal Revenue Code of 1986, as amended (the "Code"); and

B. provided that the Executive is eligible for and timely elects to receive continued health coverage under the Company's health plan under the Consolidated Omnibus Budget Reconciliation Act ("COBRA"), and the Executive pays the full monthly COBRA premium cost for such health coverage, the Company shall reimburse the Executive monthly an amount equal to the monthly COBRA premium paid by the Executive, less the amount that the Executive would be required to contribute for similar coverage under the Company's medical plan if the Executive were an active employee for the Company, for the Severance Period, or until the Executive becomes employed by another employer offering any such benefits (whichever is earlier). The Executive agrees to provide the Company with notice of eligibility under another health plan within two (2) weeks of such eligibility. Such amounts shall commence on the sixtieth (60th) day after the Executive's effective date of termination, with the first such installment payment including any unpaid severance payments that would have been made on the normal payroll dates occurring during the first sixty (60) days following the date of termination. Notwithstanding the foregoing, the Company reserves the right to restructure the foregoing reimbursement arrangement in any manner necessary or appropriate to avoid penalties or adverse tax consequences to the Executive or the Company or any affiliate, as determined by the Company in its sole discretion.

(ii) *Qualifying Termination In Connection with Change of Control.* If the Qualifying Termination occurs on the date of, or within 12 months after, the effective date of a Change of Control (a "CoC Qualifying Termination"), the Executive shall be entitled to the same payments and benefits set forth under Section 4a(i) above, except that (A) the Severance Period for purposes of Sections 4a(i)(A) and (B) shall extend for twelve (12) months instead of the period set forth in Section 4a(i)(A), (B) the continued salary payments in Section 4a(i)(A) shall be paid in a lump sum within sixty (60) days following the Executive's termination date, instead of in the form of installment payments, (C) the Executive shall be entitled to a lump sum payment equal to the Executive's target Annual Bonus for the year in which the Executive's CoC Qualifying Termination occurs, payable within sixty (60) days following the Executive's termination date, and (D) each equity award granted to the Executive under the Equity Plan shall automatically vest in full upon the CoC Qualifying Termination.

(iii) *Disability.* If the Executive's employment under this Agreement terminates due to a disability pursuant to Section 2c, either before or after a Change of Control, the Executive shall be entitled to the same payments and benefits set forth under Section 4a(i) above.

(iv) *No Duplication of Benefits.* Notwithstanding anything to the contrary, the Executive shall be eligible to receive payments under subsection (i), (ii), or (iii) of this Section 4a (and, for the avoidance of doubt, shall not be eligible to receive payments under more than



one such subsection). Additionally, the Executive shall not be eligible to participate in the Company's Change of Control Severance Plan, or any successor plan.

**b. Execution of Release.** The Executive shall not be entitled to any payments or benefits under Section 4a unless the Executive executes and does not revoke a Release and Agreement (the "Release"), as drafted by the Company at the time of the Executive's termination of employment, including, but not limited to:

(i) an unconditional release of all rights to any claims, charges, complaints, or grievances, known or unknown to the Executive, against the Company or its affiliates or assigns, through the date of the Executive's termination from employment other than post termination payments and benefits pursuant to this Agreement;

(ii) a representation and warranty that the Executive has not filed or assigned any claims, charges, complaints, or grievances against the Company or its affiliates, or assigns;

(iii) an agreement not to use, disclose, or make copies of any confidential information of the Company, as well as to return any such confidential information and property to the Company upon execution of the Release; and

(iv) an agreement to indemnify the Company, or its affiliates or assigns, in the event that the Executive breaches any portion of the Agreement or Release.

**c. No Admission.** The Executive acknowledges such a Release shall not be construed as an admission by the Company or any other releasee of any wrongdoing whatsoever against the Executive, and all of the releasees specifically deny any such wrongdoing.

**d. Definition of Change of Control.** As used in this Agreement, the term "Change of Control" means:

(i) any merger or consolidation in which voting securities of the Company possessing more than 50% of the total combined voting power of the Company's outstanding securities are transferred to a person or persons different from the person holding those securities immediately prior to such transaction and the composition of the Board following such transaction is such that the directors of the Company prior to the transaction constitute less than 50% of the Board membership following the transaction;

(ii) any acquisition, directly or indirectly, by a person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership of voting securities of the Company possessing more than 50% of the total combined voting power of the Company's outstanding securities; provided, however, that, no Change of Control shall be deemed to occur by reason of the acquisition of shares of the Company's capital stock by an investor or group of investors in the Company in a capital-raising transaction; or

(iii) any sale, transfer, exclusive worldwide license or other disposition of all or substantially all of the assets of the Company.

e. **Parachute Provisions.** In the event the Company determines in good faith that any payments or benefits (whether made or provided pursuant to this Agreement or otherwise) (“Total Payments”) provided to the Executive would otherwise exceed the amount (the “Safe Harbor Amount”) that could be received by the Executive without the imposition of an excise tax under section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), then the Total Payments shall be reduced to the extent, and only to the extent, necessary to assure that their aggregate present value, as determined in accordance the applicable provisions of section 280G of the Code and the regulations thereunder, does not exceed the greater of the following dollar amounts: (i) the Safe Harbor Amount, or (ii) the greatest after-tax amount payable to the Executive after taking into account any excise tax imposed under section 4999 of the Code on the Total Payments. The Company shall pay all of the fees, including legal and accounting fees, associated with calculating the amounts set forth in this subsection 4e.

## SECTION 5. CONFIDENTIALITY AND INVENTIONS

a. **Confidential Information.** Confidential Information means trade secrets, know-how, and other information relating to the Company’s business and not generally available to the public, which is disclosed to the Executive or with which the Executive becomes familiar during the Executive’s term of employment with the Company. Confidential Information includes information relating to the Company’s business practices and prospective business interests, products, processes, equipment, manufacturing operations, marketing programs, research, product development, and engineering. From the date of this Agreement and during or after the Executive’s term of employment, unless the Executive receives the Company’s written consent or except as permitted by Section 5(e), the Executive will not disclose, use, disseminate, lecture upon, or publish any part of the Company’s Confidential Information, whether or not developed by the Executive. Also, the Executive will have the same obligations with respect to the secret or confidential information of any other company or individual (including the Company’s parent company), to which the Executive gains access in connection with the Executive’s employment. The Executive agrees that the Executive will not disclose to the Company or induce the Company to use any secret confidential information of others, including former employers, with whom the Executive has obligations of secrecy. The Executive expressly agrees to be solely and individually liable to any previous employers for any breach of the Executive’s obligations to those previous employers, contractual or otherwise.

b. **Inventions.** Inventions means discoveries, improvements, and ideas, whether patentable or not, made by the Executive solely or jointly with others, that relate to the business of the Company, including any of its products, processes, equipment, manufacturing operations, marketing programs, research, product development, or engineering activities. The Executive agrees that the Executive will promptly disclose to the Company all Inventions (including those in the formative stages) that relate to the business of the Company made during the Executive’s term of employment whether or not during the Executive’s normal working hours. The Executive agrees that the Executive will also promptly disclose to the Company any Inventions that relate to the business of the Company made during the period of one (1) year after the termination of the term of the Executive’s employment that relate to or constitute an improvement upon the Company’s Confidential Information. The Executive shall keep and maintain written records concerning such Inventions and make these available to the Company at

all times. The Company will hold such written records with the same degree of care as it does with other business documents of a confidential nature.

**c. Assignment of Inventions.** Inventions made in accordance with this Section 5 shall be the sole and exclusive property of the Company, except that the Executive shall retain full rights and title to any Inventions to which all of the following conditions apply:

- (i) no equipment, supplies, facilities, or Confidential Information of the Company was used in the Invention's development;
- (ii) the Invention was developed entirely on the Executive's own time;
- (iii) the Invention does not relate to the Company's business or to the Company's actual or clearly anticipated research and development program; and
- (iv) the Invention does not result from any work performed by the Executive for the Company.

During and after the Executive's term of employment, the Executive or the Executive's legal representative shall, at the Company's request and expense, execute domestic and foreign patent applications and assignments to the Company concerning Inventions owned by the Company under this section, and take all other actions as the Company may request to perfect and maintain the Company's rights in same.

**d. Documents.** The Executive acknowledges that all originals and copies of drawings, blueprints, manuals, reports, notebooks, computer programs, photographs and any other recorded, written, or printed matter relating to research, manufacturing operations, or the business affairs of the Company made or received by the Executive during the Executive's employment are the property of the Company. The rights comprised in the copyright of any of the above documents made by the Executive during the Executive's employment shall be owned exclusively by the Company. The Executive agrees to promptly surrender such property at the request of the Company and will not retain such property or copies thereof after termination of the term of the Executive's employment. The Executive agrees to similarly return all other property of the Company such as equipment, samples, and models.

**e. Permitted Conduct.** Nothing in this Agreement, including in this Section 5, restricts or prohibits the Executive or the Executive's counsel from initiating communications directly with, responding to any inquiry from, volunteering information to, or providing testimony before a self-regulatory authority or a governmental, law enforcement, or regulatory authority, including the U.S. Equal Employment Opportunity Commission ("EEOC"), the Department of Labor ("DOL"), the National Labor Relations Board ("NLRB"), the Department of Justice ("DOJ"), the Securities and Exchange Commission ("SEC"), FINRA, the Congress, and any agency Inspector General (collectively, the "Regulators"), from participating in any reporting of, investigation into, or proceeding regarding suspected violations of law, or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. The Executive does not need the prior authorization of the Company to engage in such communications with the Regulators, respond to such inquiries from the

Regulators, provide Confidential Information or documents containing Confidential Information to the Regulators, or make any such reports or disclosures to the Regulators. The Executive is not required to notify the Company that the Executive has engaged in such communications with the Regulators. The Executive recognizes and agrees that, in connection with any such activity outlined above, the Executive must inform the Regulators that the information the Executive is providing is confidential. Despite the foregoing, the Executive is not permitted to reveal to any third-party, including any governmental, law enforcement, or regulatory authority, information the Executive came to learn during the course of the Executive's employment with the Company that is protected from disclosure by any applicable privilege, including but not limited to the attorney-client privilege and/or attorney work product doctrine. The Company does not waive any applicable privileges or the right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information.

#### **SECTION 6. RESTRICTIVE COVENANT**

During the Restricted Period, the Executive shall not engage in any "competitive business." As used in this Agreement, a "competitive business" shall mean any business that is engaged in the research, development, manufacturing, distribution, licensing or sale of technology, products, or services relating to hormonal contraception; provided, however, that a "competitive business" shall not include the acquiring, surviving, or licensing company in a Change of Control transaction if the Executive shall become an employee of or a consultant to such company with the knowledge and consent of the Company. For purposes of this Agreement, the term "Restricted Period" shall mean the period from and after the date of this Agreement and through the six (6) month period after the termination of the term of the Executive's employment hereunder, provided that the Restricted Period shall be for a period of twelve (12) months (instead of six (6) months) after January 1, 2020 or after the termination of the term of the Executive's employment hereunder if the Executive has a CoC Qualifying Termination.

#### **SECTION 7. NON-SOLICITATION**

**a. Non-Solicitation of Customers.** During the Restricted Period, the Executive shall not solicit, entice or induce any person, firm or company with which or for which, at any time during the twelve (12) months immediately preceding the termination, the Executive has had personal dealings, contact or responsibility as a customer or client of the Executive, and in respect of whom the Executive has had access to confidential information to become in competition with the Executive or to become a client or customer of the Executive or any other person, firm, company, or association with whom the Executive has an interest, and the Executive shall not approach any such person, firm, company, or association for any such purpose or authorize or knowingly approve the taking of such actions by any other person or entity.

**b. Non-Solicitation of Employees.** During the Restricted Period, the Executive shall not solicit, entice, or induce any person, whom at any time during the twelve (12) months immediately preceding the termination, was and remains an employee of the Company in a senior managerial capacity, or as a highly skilled employee with access to and responsibility for

any confidential information, to become employed or engaged by the Executive or any person, firm, company, or association in which the Executive has an interest, and the Executive shall not approach any such person for any such purpose or authorize or knowingly approve the taking of such actions by any other person or entity.

#### **SECTION 8. REPRESENTATION AND WARRANTY BY THE EXECUTIVE**

The Executive hereby represents and warrants to the Company, the same being part of the essence of this Agreement that, as of the date of this Agreement, the Executive is not a party to any agreement, contract, or understanding, and that no facts or circumstances exist, that would in any way restrict or prohibit the Executive in any material way from undertaking or performing any of the Executive's obligations under this Agreement. The foregoing representation and warranty shall remain in effect throughout the term of the Executive's employment hereunder.

#### **SECTION 9. REMEDIES**

**a. Equitable Relief.** The parties acknowledge and agree that irreparable harm would result in the event of a breach or threat of a breach by the Executive of Section 5, 6, 7, or 10 or the making of any untrue representation or warranty by the Executive in this Agreement. Therefore, in such an event, and notwithstanding any other provision of this Agreement:

(i) the Company shall be entitled to a restraining order, order of specific performance, or other injunctive relief, without showing actual damage and without bond or other security; and

(ii) the Company's obligation to make any payment or provide any benefit under this Agreement, including without limitation any severance benefits, shall immediately cease.

**b. Remedies Not Exclusive.** The Company's remedies under this Section 9 are not exclusive, and shall not prejudice or prohibit any other rights or remedies under this Agreement or otherwise. To the extent required to be enforceable by applicable law, the cessation of the Company's obligation to make payments or continue benefits under this Section 9 shall be deemed to be in the nature of liquidated damages.

#### **SECTION 10. RETURN OF COMPANY PROPERTY**

Immediately upon termination of the term of the Executive's employment or upon the Company's earlier request, the Executive shall return to the Company all Confidential Information and other items described in Section 5 and all originals and copies of any other property or information owned by the Company or relating to its business, that the Executive has in the Executive's possession or under the Executive's control, including all credit cards, papers, books, equipment, files, and samples. To the extent that the Executive made use of the Executive's own personal computing device(s) (e.g., PDA, laptop, iPad, thumbdrive, etc.) during and in connection with the term of the Executive's employment, the Executive agrees to deliver such personal computing device(s) to the Company for review and permit the Company to delete all of the Company's Confidential Information from such personal computing device(s), and/or

permit the Company to remotely delete all of the Company's Confidential Information from such personal computing device(s).

#### SECTION 11. MISCELLANEOUS PROVISIONS

- a. Notices.** Unless otherwise agreed in writing by a party entitled to notice, all notices required by this Agreement shall be in writing and shall be deemed given when physically delivered to and acknowledged by receipt by a party or its duly authorized attorney or legal representative, or when deposited postage paid, registered or certified mail, addressed to the party at its principal business or residence as set forth in the Company's records or as known to or reasonably ascertainable by the party required to give notice.
- b. General Rules of Construction.** The parties have participated jointly in negotiating and drafting of this Agreement. If a question concerning intent or interpretation arises, no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authorship. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all related rules and regulations unless the context requires otherwise.
- c. Meaning of Certain Words.** The word "including" shall mean "including without limitation."
- d. Waivers.** No assent, express or implied, by any party to any breach or default under this Agreement shall constitute a waiver of or assent to any breach or default of any other provision of this Agreement or any breach or default of the same provision on any other occasion.
- e. Binding Effect; No Third Party Beneficiaries.** This Agreement shall bind and benefit the parties and their respective heirs, devisees, beneficiaries, grantees, donees, legal representatives, successors, and assigns. Nothing in this Agreement shall be construed to confer any rights or benefits on third party beneficiaries.
- f. Assignment.** Neither party may assign this Agreement or any interest herein without the other's prior written consent; provided that the Company may assign its interest to another entity that it controls, is controlled by, or is under common control with or to a successor in interest upon a Change of Control.
- g. Captions.** Titles or captions contained in this Agreement are for convenience and are not intended to affect the substantive meaning of any provision.
- h. Severability.** If any provision of this Agreement, including the Confidential Information provision of this Agreement, is found in binding arbitration or by a court or other tribunal of competent jurisdiction to be invalid or unenforceable, the attempt shall first be made to read that provision in such a way as to make it valid and enforceable in light of the parties' apparent intent as evidenced by this Agreement. If such a reading is impossible, the tribunal having jurisdiction may revise the provision in any reasonable manner, to the extent necessary to make it binding and enforceable. If no such revision is possible, the offending provision shall be

deemed stricken from the Agreement, and every other provision shall remain in full force and effect.

**i. Counterparts.** This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

**j. Survival.** The provisions of this Agreement that by their terms are intended to continue beyond the termination of the term of the Executive's employment shall survive such termination of employment and shall continue in effect for the respective periods therein provided or contemplated.

**k. Tax Withholding.** All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state, and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. The Executive shall be solely responsible for all federal, state, and local taxes due with respect to any payment received under this Agreement or otherwise in connection with the Executive's employment.

**l. Section 409A.** This Agreement is intended to comply with the requirements of Section 409A of the Code and the regulations thereunder ("Section 409A"), and shall in all respects be administered in accordance with Section 409A. Notwithstanding anything in this Agreement to the contrary, distributions may only be made under this Agreement upon an event and in a manner permitted by Section 409A or an applicable exemption. If the payment of severance benefits would otherwise be accelerated under this Agreement and paid in a lump sum upon a Change of Control, and such Change of Control is not a "change in control event" under Section 409A, such severance payments shall not be accelerated and shall instead be paid on the regularly scheduled payment date. Severance benefits provided under this Agreement are intended to be exempt from Section 409A under the "separation pay exception" to the maximum extent applicable. Further, any payments that qualify for the "short-term deferral" exception or another exception under Section 409A shall be paid under the applicable exception. All separation payments to be made upon a termination of employment under this Agreement may only be made upon a "separation from service" under Section 409A. For purposes of Section 409A, each payment hereunder shall be treated as a separate payment and the right to a series of payments under this Agreement shall be treated as a right to a series of separate payments. With respect to payments that are subject to Section 409A, in no event may the Executive, directly or indirectly, designate the calendar year of a payment, and if a payment that is subject to execution of a Release Agreement could be made in more than one taxable year, payment will be made in the later taxable year. If and to the extent that reimbursements or other in-kind benefits under this Agreement constitute "nonqualified deferred compensation" for purposes of Section 409A, such reimbursements or other in-kind benefits shall be made or provided in accordance with the requirements of Section 409A. Notwithstanding the foregoing, although the Company has made every effort to ensure that the payments and benefits provided under this Agreement comply with Section 409A, in no event shall the Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Executive on account of non-compliance with Section 409A.

m. **Governing Law.** This Agreement shall be governed by and construed under the laws of the United States and the State of New Jersey.

n. **Board Information.** The Executive shall at all times promptly give to the Board (in writing if so requested) all such information as it may require in connection with matters relating to the Executive's employment or with the Company or the business of the Company.

o. **Effective Date.** This Agreement shall be effective immediately on the date duly executed by both parties.

p. **Full Agreement; Modification.** This Agreement constitutes the entire agreement of the parties concerning its subject matter and supersedes all other oral or written understandings, discussions, and agreements, and may be modified only in a writing signed by both parties. The parties acknowledge that they have read and fully understand the contents of this Agreement and execute it after having an opportunity to consult with legal counsel.

q. **Counterparts; Delivery.** This Agreement may be executed by the parties in separate counterparts and may be delivered by either or both parties by facsimile or electronic transmission.

(Signature page follows.)



IN WITNESS WHEREOF, and intending to be legally bound hereby, the parties have executed this Agreement to be effective as of the date specified above.

AGILE THERAPEUTICS, INC.

/S/ Dennis P. Reilly  
Name: Dennis P. Reilly

By: /S/AI Altomari  
Name: AI Altomari  
Title: Chairman and Chief Executive Officer

**SCHEDULE A**

**Permitted Activities**

<b>Description of Activity</b>	<b>Nature of Work</b>	<b>Hours Per Week</b>	<b>Anticipated Compensation</b>
A-1			

**CERTIFICATION OF PERIODIC REPORT  
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Alfred Altomari, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Agile Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 28, 2019

/s/ Alfred Altomari  
\_\_\_\_\_  
Alfred Altomari  
Chief Executive Officer  
Principal Executive Officer

---

**CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE  
SARBANES-OXLEY ACT OF 2002**

I, Dennis P. Reilly, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Agile Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 28, 2019

/s/ Dennis P. Reilly  
Dennis P. Reilly  
Chief Financial Officer  
Principal Financial and Accounting Officer

---

**STATEMENT OF CHIEF EXECUTIVE OFFICER OF  
AGILE THERAPEUTICS, INC.  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Agile Therapeutics, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2019 as filed with the Securities and Exchange Commission (the "Report"), I, Alfred Altomari, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

- 1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 28, 2019

/s/ Alfred Altomari  
\_\_\_\_\_  
Alfred Altomari  
Chief Executive Officer  
Principal Executive Officer

---

**STATEMENT OF CHIEF ACCOUNTING OFFICER OF  
AGILE THERAPEUTICS, INC.  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Agile Therapeutics, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2019 as filed with the Securities and Exchange Commission (the "Report"), I, Dennis P. Reilly, Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

- 1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 28, 2019

/s/ Dennis P. Reilly  
Dennis P. Reilly  
Chief Financial Officer  
Principal Financial and Accounting Officer

---